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ABSTRACT
During menopause, many women experience weight gain which is mostly 
in the form of abdominal and upper body fat deposition. This phenomenon has 
been recognized as an independent predictor of cardiovascular disease in 
females. Other disease processes, such as diabetes, hypertension and some 
cancers, specifically, breast and esophageal have been linked to obesity. Thus, 
the occurrence of increased body fat is placing the postmenopausal female in 
jeopardy of a potential life-threatening position. The connection between the lack 
of estrogen seen in menopause and weight gain remains unclear, but studies have 
shown that estrogen status may affect carbohydrate and fat metabolism. This 
study examined the metabolic responses at rest and during a low-to-moderate 
intensity cycle ergometer exercise session of thirty-two premenopausal females 
at different levels of estrogen status. Eleven subjects (Group M) were tested 
during day 1 thru 4 of their menses which represented low estrogen status; 
fourteen subjects (Group F) were tested during the follicular phase (day 8 thru 12) 
which represented high estrogen status; and 7 subjects (Group G) who were being 
treated with a GnRH agonist analogue (Depot Lupron) to suppress estrogen 
synthesis, were tested to represent the post-menopausal female. Estrogen status 
was confirmed by blood analysis for all subjects.
Testing consisted of a 15-minute rest period and a 20 minute submaximal 
cycle ergometer test. The exercise protocol consisted of 2 minute staged 
increments of 10 watts, beginning at 0 watts, until the subject reached between 60 
and 70% of her age-predicted maximum heart rate (220 minus age). Respiratory
ix
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gases were analyzed using the Quinton QMC™ metabolic cart in the breath-by- 
breath mode. Blood was drawn at the end of the rest session, at 10 minutes and 
20 minutes of exercise.
Results indicated that the pseudomenopausal model demonstrated non­
significant differences in fuel substrate utilization. It is possible that the lack of 
estrogen is not an underlying factor of the weight gain seen in menopause, but 
further investigation is required.
x
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CHAPTER 1. INTRODUCTION
Many women experience weight gain at the time of menopause. Some 
investigators have found that the body mass index (BMI) is significantly higher than 
the ideal value in climacteric (the transition from late fertile age to advanced 
natural post-menopause) women, and that menopause seems to be a weight-gain 
inducing co-factor (de Aloysio, et al„ 1987). It has been suggested that 
postmenopausal females may be heavier than their younger premenopausal 
counterparts because of obscure reasons attributed to the aging process and 
changes in lifestyle (Gaspard, 1994). This includes a general decrease in activity 
levels which may be related to aging. Without a concomitant decrease in energy 
intake, this factor could lead to increased storage of energy as fat. Moreover, if 
activity decreases, it is probable that musculature also decreases accordingly. 
Since basal and resting metabolic rates (minimum energy expenditure required to 
maintain bodily cellular functions) are directly related to the amount of lean, 
metabolically active, tissue (Shutz, 1993), it follows that basal and resting energy 
expenditure will decrease. This could be a valid explanation for weight gain if 
dietary habits are unchanged. Another plausible connection to the weight gain 
may be an increased consumption of calories due to increased appetite, which, if 
more than calorie expenditure, ultimately leads to increased weight in the form of 
fat. In addition, aging has been shown to be associated with detrimental changes 
in glucose tolerance and subsequent weight gain, but training studies involving the 
elderly described a reversal of these changes, thus indicating that lifestyle may be 
more of a factor than aging perse (Davidson, 1979; DeFronzo, 1979).
1
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2While all of the above reasons may offer insight into postmenopausal 
weight gain, there may also be very important, although subtle, metabolic 
changes that develop concurrently with the hormonal alterations that occur during 
the menopause that are not age-related. Even though training has been shown 
to eliminate the decremental effects of aging as cited above, many studies have 
shown that menopause has an appreciable effect on insulin and glucose 
metabolism (Gaspard, 1994; Stevenson, et a I., 1994) as well as lipid metabolism 
(Jensen, 1994). The major hormonal alteration is decreased estrogen synthesis 
that results from natural ovarian failure that occurs during menopause. Senoz and 
associates (1996) found that estrogen deprivation rather than age, is responsible 
for the poor lipid profile and carbohydrate metabolism in postmenopausal women. 
These effects could alter the body’s use of fuel substrates, both in exercise as 
well as resting metabolism, and could adversely affect body fat weight.
If postmenopausal weight gain is caused by alterations in metabolism, it is 
reasonable to suspect that the body prefers to use carbohydrate, thus sparing fat 
and directing it to storage in fat cells (adipocytes). The amount of carbohydrate 
and fat being used as a fuel substrate (oxidized ) may be quantified by a method 
termed indirect calorimetry. This method of ascertaining fuel substrate utilization 
requires the measurement of oxygen consumption and carbon dioxide production, 
the ratio of which (VCOj/VO^ is called the respiratory quotient (RQ or R), and is 
described in the Methods section of Chapter 3.
The predominant fuel source at rest is lipid and the R value is close to 0.70. 
As intensity of exercise increases, carbohydrate becomes more important, and the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3R value approaches unity. There is a mid-point where half the fuel being oxidized 
is carbohydrate and the other half is lipid. This has been termed the “crossover 
point” and is the power output at which energy from carbohydrate predominates 
over energy from lipid, with further increases in power eliciting a relative increment 
in carbohydrate utilization and concomitant decrement in lipid oxidation (Brooks 
& Mercier, 1994).
It is apparent that age is an unavoidable confounding factor when studying 
the postmenopausal female. An alternative, therefore, is to use a 
psudomenopausal model which eliminates the factor of age. Such a model is 
represented by female patients who are being treated for endometriosis with a 
GnRH agonist analogue (GnRHaa) such as leuprolide acetate (Lupron Depot; TAP 
Pharmaceuticals, Deerfield, IL). Levels of circulating estrogens are suppressed 
to menopausal range within 4 weeks of initiation of this therapy (Surrey, et ai, 
1995). This group can then be compared to premenopausal, eumenorrheic 
females during menses and follicular phases of their cycles, representing a range 
of estrogen levels.
The purpose of this study was to determine the influence of estrogen levels, 
independent of age, on physiological, metabolic parameters at rest and during 
submaximal exercise that would indicate a rationale for increasing fat weight. The 
criterion dependent variable under study was the R value. Changes in the 
following factors were also determined in order to obtain a profile of the in vivo 
environment at various levels of estrogen within different levels of energy 
expenditure: blood levels of cortisol, glucose, lactate, ammonia, hematocrit;
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4cardiorespiratory factors of heart rate and percent of age-predicted maximum 
heart rate; and metabolic factors of percent of fuel substrate utilization obtained 
from carbohydrate sources, resting energy expenditure (kilocalories expended per 
day), kilocalories expended per liter of oxygen and kilocalories expended per 
minute.
It was hypothesized that hypoestrogenism may result in higher R values 
during rest and submaximal exercise at various absolute and relative workloads 
thus representing an overall preference for carbohydrate, leading to a shift in the 
proportion of substrate oxidized. Moreover, if carbohydrate is the preferred fuel 
substrate, and normal fat metabolism suffers, it may explain why the body will 
store the excess calories in adipose tissue. It was further hypothesized that if the 
postmenopausal female is preferring carbohydrate to fat, the crossover point will 
be attained sooner (at a lower power output). It was assumed that protein 
utilization is minimal (5 - 10%) and is equal among untrained individuals 
irrespective of menopausal status (See Chapter 2 for review).
It is recognized that the results of this study will be limited to the population 
from which data was gathered. Specifically, the subjects under study were 
healthy, premenopausal females between the ages of 21 and 42 who were not at 
the “athletic” level of fitness, and ranged from inactive to moderately active.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER 2. REVIEW OF LITERATURE
Estrogen levels normally decline at menopause. Since estrogen deficiency 
occurs at menopause, and increased body weight may be demonstrated at this 
time, it is easy to observe a link between hypoestrogenism and weight gain. 
However, this could be a simple coincidence, with no ‘‘cause’’ of weight gain 
being attributed to the lack of estrogen.
Common menopausal symptoms of hot flushes, depression, changes in 
balance and limb coordination, and decreased alertness have been shown to be 
attenuated or completely alleviated using estrogen replacement therapy (ERT) 
(Backstrom, 1995). Research trials using ovariectomized animal models have 
demonstrated that weight gain is also diminished with the administration of high 
doses of estrogen (Kendrick, etal., 1987; Perry, etal., 1979; Wade, 1975). Even 
though the mechanism of action is not clear, estrogen may have an effect on how 
the body uses energy. The present study investigated the differences between 
pre- and postmenopausal use of energy for the purpose of identifying metabolic 
reasons for weight gain commonly seen in the postmenopausal years.
The Biochemistry and Synthesis of Estrogen
There are basically two categories of hormones produced by the body, 
steroid and nonsteroid. Nonsteroid hormones include amino acid derivatives, 
peptides, glycoproteins and eicosanoids. Steroid hormones are cyclic 
hydrocarbon derivatives of cholesterol and include progestins, androgens, 
corticosteroids and estrogens. Estrogens are a family of female sex hormones 
which are synthesized primarily in the ovaries of adult women before the onset of
5
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menopause. The estrogen molecule has a four ring aromatic structure derived 
from cholesterol. Its synthesis begins with cholesterol and proceeds through 
several stages of reactions before reaching the final product of estrogen. 
Essentially, the 21-carbon cholesterol molecule is cleaved of its carbon chain, is 
hydroxylated, reduced, oxidized, isomerized, and finally, aromatized to form an 
18-carbon estrogen molecule. Highly specific enzymes, as well as NADPH and 
O2 are required in these reactions. A simplified flow of estrogen synthesis from 
cholesterol is shown in Figure 2.1.
Although six different natural estrogens have been isolated from the human 
female, only three forms (estradiol, estrone, and estriole) are present in significant 
quantities {Facts and Comparisons, 1995). Their differences are found on carbons 
C16 and C17 of the D ring. The strengths of their action are also different. Estradiol 
has 12 times the estrogenic potency of estrone, and 80 times that of estriole 
(Guyton, 1986).
Estradiol, also termed E2, 17(3-hydroxysteroid, or estradiol-170, is not only 
the most potent estrogen, but is the most predominant form produced by the body. 
The terms “estrogen” and “estradiol" are, therefore, used interchangeably. 
Premenopausal blood levels of estradiol depend on the day of the menstrual 
cycle, the approximate range being 100 - 700 pg/ml (Guyton, 1986). Blood 
estradiol concentrations are lowest during menses, rise during the proliferative, 
follicular phase, and peak before ovulation (Figures 2.2 and 2.3). The level
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Sexual Cycle. Source: Adapted from Guyton, 1986.
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10
of estrogen that elicits menstrual bleeding and development of endometrium varies 
among individuals, but a continuous serum concentration of greater than 100 
pmol/l will usually have these effects (Backstrom, 1995). Table 2.1 defines 
typical or “expected" values of estrogen at different phases in the menstrual cycle 
and compares them with postmenopausal values and those of males.
Estradiol is rapidly oxidized to a weaker estrogen form, estrone. Small 
amounts of estrone are secreted by the thecal and stromal cells of the ovaries 
(Guyton, 1986) of the premenopausal female, but most estrone is synthesized in 
the peripheral tissues from androgens secreted by the adrenal gland. Estrone and 
estradiol are interconverted by the enzyme estradiol-17B-hydroxysteroid 
dehydrogenase (Bayard, et al., 1995) which favors estrone production. Estriole, 
the weakest form of estrogen, is an oxidative product derived from either estradiol 
or estrone, and this conversion occurs mainly in the liver (Guyton, 1986). 
Ultimately, estrogens are conjugated in the liver to form glucuronides and sulfates 
which are excreted in the urine and bile.
The postmenopausal range of serum E2 is less than 125 pmol/l (Matta, et 
al., 1988) or 25.0 ± 8.0 pg/ml (Dumesic & Matteri, 1993) and a mean 
postmenopausal value has been found to be 0.03 (30 pmol/l)± 0.01 nmol/L 
(Rebuffe-Scrive, et al., 1986). Ovarian steroidogenesis contributes little to this 
circulating pool (Judd, et al., 1976). After the onset of menopause, the ovaries 
usually produce very little estrogen, but continue to produce androgens, especially 
testosterone and androstenedione, by the ovarian stromal and hilus cells which
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Table 2.1. Summary of Expected Estradiol Values
Estrogen 
Status of:
n Central 95th 
Percentile (pg/ml)
Entire Range 
(pg/ml)
Normally
Menstru­
ating
Females
Follicular
Phase
178 25*-145 25* - 221
Mid-
Cycle
Peak
150 112-443 83 - 690
Luteal
Phase
210 48 - 241 26-408
Postmenopausal
Females
71 25* - 59 25* - 86
Males 103 25* - 50 25* - 70
‘Values of less than the sensitivity of the assay reported as 25 pg/ml.
Source: Adapted from Abbott Laboratories Diagnostics Division, Abbott Park, IL, 
IM®x Assay Insert.
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12
retain LH receptors (Judd, et al., 1974). Androstenedione is also produced by the 
adrenals. The androgens produced by the ovaries and adrenals are aromatized 
mainly to the estrone form of estrogen (Grodin, et al., 1973). Extragonadal 
aromatization sites that have thus far been identified, other than the adrenals, are 
adipose tissue, liver, kidney and brain and mainly involves the conversion of 
androstenedione to estrone (Grodin, et al., 1973). Most of the postmenopausal 
estrogen metabolism occurs in adipose tissue (Dumesci & Matteri, 1993). 
Vascular endothelial cells have also been shown to synthesize estrogens. These 
cells also contain functional estrogen receptors (Bayard, et al., 1995). Age and 
weight both influence extragonadal aromatization as the production of androgens 
by the adrenals declines by the age of 30 (Backstrom, 1995). Heavier women 
have higher conversion rates and higher plasma estrogen levels than thinner 
women which has been shown by a close relationship between the body mass 
index and estrogen levels (Boman, etal., 1990).
The Mechanism of Action of Estrogen
As described above, estrogen is produced in the ovaries, secreted into the 
bloodstream, and taken up by most tissues, but mainly those of sex organs and 
adipose tissue. Estrogen’s actions are varied. It is responsible for the synthesis 
of structural proteins for tissue growth, repair and maintenance of female sex 
organs, and is, therefore, anabolic. It also promotes the development of female 
sexual characteristics, including fat deposition; assists in regulating the 
menstrual cycle, specifically, the proliferative phase of the menstrual cycle; and 
participates in oogenesis, ovulation, and many changes during pregnancy. In
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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addition, estrogen indirectly contributes to the integrity of the skeleton by 
conserving calcium and phosphorus and encouraging bone formation (Facts and 
Comparisons, 1995).
Estrogen is lipid soluble and can, therefore, pass easily through the target 
cell’s membrane into the cytosol where the specific estrogen receptors are found. 
Its primary effects, like all steroid hormones, are on gene expression rather than 
on enzyme activities or transport processes (Stryer, 1988). Hence, the newly 
formed hormone-receptor complex enters the nucleus of the cell, binds to a 
particular enhancer section of the cell’s DNA, and activates certain genes. In 
response to this direct activation, mRNA is synthesized and exits the nucleus into 
the cytoplasm, where it promotes protein synthesis.
Even though estrogen has a wide variety of effects on different organs, 
estrogen receptors are encoded by a single gene and are members of the 
steroid/thyroid hormone receptor superfamily which also include receptors for 
active metabolites of vitamins A and D (Evans, 1988). To achieve its diversity of 
action, it is postulated that a second mediator of estrogen action, the estrogen 
receptor-regulated transcription factor which amplifies the action of estrogen, 
forms a cascade of gene regulation to provide diverse and specific pathways in 
each target organ (Muramatsu, 1995).
Recently, estrogen receptors have also been found on the plasma 
membranes of cells of the endometrium, liver, pituitary, and other tissues (Baulieu 
& Robe!, 1995). This type of hormone-receptor complex causes more of a short­
term effect, i.e., within minutes, compared to the intracellular hormone-receptor
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complex, i.e., hours, and it is not known what effect, if any, is being 
demonstrated.
Estroaen Regulation and Control
Female sex hormones are intricately regulated by negative and positive 
feedback as well as neural mechanisms and depend on menstrual cycle phases 
(See Figure 2.4). There are at least three separate organs which are important in 
the regulation of estrogen synthesis and release: (1) the hypothalamus, (2) the 
adenohypophysis (anterior pituitary), and (3) the ovaries.
The hypothalamus synthesizes and releases two gonadotropin releasing 
hormones, follicle-stimulating hormone releasing hormone (FSHRH) and 
luteinizing hormone releasing hormones (LHRH) in a pulsatile fashion. 
Collectively, these two hormones are called gonadotropin releasing hormones, or 
GnRH. They are believed to be part of one hormone complex with different active 
sites which are specific to their particular receptors. The release of GnRH is 
modulated by both negative and positive feedback mechanisms: It is directed by 
both neural input and circulating levels of the hormones, progesterone and 
estrogen, FSH and LH, as well as levels of GnRH.
The anterior pituitary has specific receptors for both FSH- and LH-releasing 
hormones. The hormone-receptor complex initiates and stimulates the pituitary 
to release one or both of the gonadotropins, FSH and LH. Generally, these two 
hormones are responsible for the cyclic nature of ovulation and the menses, as 
well as of the secretion of estrogen and progesterone by the ovaries. Normal
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Figure 2.4. Estrogen Regulation and Control
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plasma levels are also cyclic. Ovaries which are not stimulated by gonadotropic 
hormones remain completely inactive (Guyton, 1986).
When FSH and LH reach the ovaries, they attach to their specific receptors 
in cell membranes. Estrogen synthesis and secretion is dependent on the activity 
of FSH and LH acting on the maturing follicle and corpus luteum during the 
menstrual cycle. Some estrogen is secreted by the corpus luteum during the luteal 
phase of the menstrual cycle, after ovulation, but most of the estrogen is secreted 
by the ovarian follicle before ovulation.
Hormonal Changes at Menopause
At the time of menopause, the hormone milieu changes. The ovary no 
longer contains viable primordial follicles, and therefore does not depend on the 
gonadotropins to nurture the follicle’s development, hence, ovulation does not 
take place. The major consequence is cessation of ovarian estrogen production. 
Since follicular estrogen production is diminished, the hypothalamus only receives 
negative feedback of decreased estrogen status. Therefore, the hypothalamus 
continues to secrete GnRH, and the pituitary continues to respond with a higher 
than normal FSH and LH release. In fact, an increase in early follicular and mid­
cycle levels of FSH is a marker of the aging ovary (Sherman, et al, 1976).
Acute Responses of Estrogen to Exercise
Changes in plasma levels of estrogen during exercise have been found to 
depend on the phase of the menstrual cycle, the training status of the individual, 
and the intensity of exercise. During the luteal phase, estrogen levels have been 
shown to rise with intensity and to level off during exhaustive exercise (Figure
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2.5). In the follicular phase, however, exercise-induced increases in estrogen 
have been shown to be significant only at exhaustion (Jurkowski, et al., 1978). 
During the menses, no changes have been observed in estrogen concentrations 
during thirty minutes of exercise at an intensity of 74% V 02max (Bonen, et al., 
1979). There is also a demonstrated difference in estrogen response due to 
training status of premenopausal women. Bonen and associates (1979) showed 
that heavy exercise in untrained subjects provoked a significant increase in 
estrogen levels, whereas trained subjects did not elicit an estrogen response at the 
same absolute workload.
Changes in Fuel Substrate Metabolism at Menopause
Even though carbohydrate is actually preferred, especially at higher 
intensities of exercise, fat is readily used to preserve carbohydrate stores as well 
as protein stores, i.e., lean tissue, or lean body mass, at lower intensities. 
Therefore, fatty acids are the main fuel substrates used at rest and during 
submaximal (light) activities. They are derived from circulating blood lipids, from 
lipolysis of triglycerides in adipocytes, and from lipoprotein lipase (LPL) activity in 
fat cells stored in muscle. Because of the abundance of adipose tissue in t h e 
body, this fuel substrate is not thought to be a limiting factor in endurance 
activities.
Adipose tissue is responsive to lipolytic stimuli such as hormonal input, i.e., 
glucagon, catecholamines, growth hormone, cortisol. The response varies, 
however, depending on the location of the adipose tissue. For instance, femoral 
adipose tissue has been shown to be less responsive to lipolytic stimuli than
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Jurkowski, etal., 1978.)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
19
abdominal adipose tissue (Kather, eta!., 1977; La Fontan, etal., 1978; Rebuffe- 
Scrive, et al., 1985; and Smith, etal., 1979). However, lipoprotein lipase (LPL) 
activity has been shown to be highest in the femoral region (Guy-Grand & Rebuffe- 
Scrive, 1980; Lithell & Boberg, 1978). A comparative study performed by 
Rebuffe-Scrive and associates (1986), demonstrated that femoral adipocytes of 
premenopausal women had a higher LPL activity than their abdominal or 
mammary adipocytes. Postmenopausal females revealed no regional differences 
in LPL activity. There was a trend for the premenopausal females to have a higher 
LPL activity in the femoral region than the postmenopausal females. In response 
to norepinephrine stimulation, premenopausal females demonstrated lower 
lipolysis in the femoral region than the other regions, and lipolysis was slightly 
higher in the mammary than in the femoral and abdominal regions of the 
postmenopausal females. However, both mammary and abdominal lipolysis was 
lower in the postmenopausal females as compared to the premenopausal females 
(lipolysis of the femoral region was unchanged after menopause). From these 
results, it was hypothesized that adipose tissue distribution may be caused by 
regionally specific effects of sex steroid hormones on adipocyte metabolism. 
Furthermore, other investigators have reported an increased resting level of 
plasma free fatty acids in postmenopausal women (Morrow, et al., 1981), 
indicating either increased mobilization of adipose tissue triglyceride fatty acid 
stores or decreased free fatty acid clearance (Jensen, et al., 1994).
Results of animal studies have also indicated that estrogen replacement in 
oophorectomized rats influenced myocardial glycogen utilization during exhaustive
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exercise, with a dose response relationship, and spared tissue glycogen during 
submaximal exercise (Kendrick, et al., 1987). If hypoestrogenemia results in a 
lower initial glycogen level at the onset of exercise, due to the body’s preference 
for glucose over fat at rest it would follow that endurance exercise performance 
would be adversely affected.
Protein contribution to energy production may be relatively small but not 
insignificant. When needed for fuel, endogenous and exogenous proteins are 
catabolized to their amino acid building blocks and used as oxidative substrates 
and as gluconeogenic precursors (Dohm.ef a/., 1982,1985,1987). Several amino 
acids provide the carbon sources for gluconeogenesis during exercise and 
glycogen restitution during recovery, and others participate in important anaplerotic 
functions (Brooks, 1987). Table 2.2 displays the percentage of fuel as protein 
found by Henderson and associates (1985). These percentages were computed 
from mean data of leucine oxidation and oxygen consumption of treadmill run rats. 
Some investigators have estimated 5 -10% of the fuel for prolonged exercise is 
provided by amino adds (Lemon & Mullin, 1980). It is well established that 
leucine metabolism is affected by acute aerobic exercise and that it is a primary 
amino add source of oxidative energy (Hagg, et al., 1982; White & Brooks, 1981; 
Wolfe, et al., 1982). The adrenal cortex hormone, cortisol, exhibits the most 
potential for inducing heightened protein catabolism (Long & Lowry, 1990) in 
order to assist in maintaining blood glucose homeostasis (Brooks & Fahey, 
1985). As a “stress" hormone cortisol is released as a result of both physical and 
mental stressors, and increases the catabolic breakdown of proteins and the
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Table 2.2. Percentage of Energy Derived from Protein.
Untrained Trained
Rest 5.0 7.1
Low Intensity 
Exercise
4.2 6.0
Moderate Intensity 
Exercise
(Not reported) 6.2
SOURCE: Adapted from Henderson, etal., 1985
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formation of glucose, which in turn may enter the metabolic pool (Astrand & 
Rodahl, 1986). Blood cortisol levels, at rest, follow a arcadian rhythm pattern and 
vary considerably during the day. Furthermore, they increase during exera'se at 
a rate proportional to intensity (Brooks & Fahey, 1985).
Rationale for Using the GnRHaa Model
Since menopause occurs at an average age of 49-50 years (Leidy, 1996), 
some of the demonstrated weight gain may be unspecified effects of age. In 
order to eliminate this possible confounding factor of age, a model has been 
chosen which represents the postmenopausal female, but is of premenopausal 
age. The chosen model is a patient receiving a gonadotropic releasing hormone 
agonist analogue (GnRHaa) for the treatment of endometriosis and in relieving 
endometriotic symptoms. This treatment modality has repeatedly been shown to 
induce a reversible pseudomenopausal state (Saltiel, 1991).
The decapeptide chemical structure of GnRH was discovered in 1971. 
Agonist analogues have been synthesized and successfully used in the treatment 
of endometriosis since 1981 (Wheeler, et al., 1993). At the onset of 
administration, the GnRHaa stimulates the release of FSH and LH from the 
pituitary and results in an increase in estrogen synthesis. However, with repeated 
administration, the stimulatory effect is abolished and induces a down-regulation 
of the pituitary gonadotropin secretion. This results in a reversible state of 
oophorectomy with assodated hypoestrogenic values equal to those found in the 
postmenopausal female (Johansen, etal., 1988; Matta, etal., 1988; Monroe, et 
al., 1986; Schriock, et al., 1985; Steingold, et al., 1987). The diminished
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circulating estrogen in turn causes the abnormal endometrial tissue to atrophy, 
thus eliminating the pain associated with endometriosis. GnRH and its analogues 
also exert direct effect on the ovary by binding to its specific receptor, stimulating 
inositol phospholipid (IP 3) turnover in the granulosa cells (Imai, etal., 1993). The 
results can either be stimulatory or inhibitory, as above, depending on duration of 
treatment.
In clinical trials the GnRH agonist, depot leuprolide acetate (LA), has been
shown to be effective in reducing estrogen concentrations to postmenopausal
levels (Dumesic & Matteri, 1993; Dawood, et al., 1995). After only one week of the
administration of 3.75 mg depot LA, serum estradiol fell to postmenopausal range,
32.0 ± 4.4 pg/ml, and continued to fall to below 25.5 ± 5.0 pg/ml. Serum estradiol
levels returned to a mean of 127.4 ± 37.3 pg/ml at 3 to 4 weeks after stopping the
depot LA treatment (Dawood, et al., 1995).
Major side effects of GnRHaa therapy are typical symptoms of menopause
such as hot flashes and vaginal dryness (Matta, etal., 1987). Less common side
effects are weight gain, insomnia, decreased libido, and edema (Wheeler, et al.,
*
1993). Mineral bone loss has been reported after several months of GnRHaa 
administration (Dawood, etal., 1995; Johansen, etal., 1988; Kauppila,1993; 
Matta, etal., 1987; Wheeler, etal., 1993). Adverse changes in lipid profiles, i.e., 
increased serum cholesterol and LDL cholesterol, have also been found after 
treatment (Johansen, etal., 1988).
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Summary
The above studies show evidence that the postmenopausal female may be 
favoring glucose over fat utilization at rest, as well as during low-moderate intensity 
exercise. If this is so, the postmenopausal female may store fat more easily than 
the premenopausal female and thus have a tendency toward the development of 
obesity. If lipid utilization is depressed, weight loss programs and exercise 
prescription methods should employ strategies that take this factor into 
consideration.
In summary, the GnRH model is being used to demonstrate the influence 
of diminished estrogen levels, experienced in menopause, on resting and 
moderate exercise metabolism. The model eliminates the influence of age on 
weight gain that may be experienced during menopausal years and is expected 
to be representative of the hormone milieu found postmenopausally.
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CHAPTER 3. METHODS
Subjects
Thirty-two premenopausal women, aged 21 to 42 years (mean = 30.6) were 
recruited as volunteers to participate in one of three groups. Twenty-five of the 
women were eumenorrheic. Eleven were tested during their menses, day 1 -4  
(Group M) and fourteen were tested during the follicular phase of their cycle, day 
8 -1 2  (Group F). Seven of the women were being treated for endometriosis and 
had received* at least two GnRHaa-depot injections (all were being treated with 
depot luprolide acetate). They were recruited from the pool of patients of local 
physicians, and were otherwise healthy (Group G). Estrogen status of each 
subject was confirmed by quantitaton of plasma estradiol levels during the fasting, 
resting phase before 8:00 a.m. on the day of testing. Inclusions to the program 
were those women who were
4 Apparently healthy, with the exception of those
who were being treated for endometriosis 
♦ Between the ages of 21 and 42
4 Untrained/sedentary to moderately trained (not
participating in competitive athletic events)
4 Not taking hormone replacement therapy or
add-back therapy, or oral contraceptives
4 Non-smokers
4 Non-obese (Body Mass Index <28 kg/m2)
4 Non-hirsute
25
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♦ Eumenorrheic (normal and regular menstrual periods for the 
past year, or amenorrheic secondary to GnRHaa therapy)
Exclusions included those women who had
♦ History of heart problems other than 
asymptomatic mitral valve prolapse
♦ Smoking history within the past year
♦ Drug therapy other than GnRH agonist
♦ Hypertensive history and/or resting systolic 
BP > 140
♦ Diabetic or diagnosed borderline diabetic 
(Fasting blood glucose >110 mg/dl)
♦ Body Mass Index (BMI) ;> 28
♦ Resting HR < 50 or > 100 bpm
♦ Orthopedic problem that would inhibit 
submaximal effort on the cycle ergometer
The three groups were matched for age, body weight, height, BMI, and 
body surface area (BSA). Descriptive statistics of the three groups are found in 
Table 3.1. Signed informed consents were obtained from all participants. A copy 
of the informed consent was provided to each participant This study was 
approved by the Institutional Review Board of Louisiana State University and the 
Research and Development Council of Woman’s Hospital.
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Table 3.1. Descriptive Statistics of the Three 
Groups of Subjects.
Variable Group M 
(n=11)
Group F 
. (n=14)
Group G 
(n-7)
Age (yr) 31.5 ±5.66  
(21-39)
31.3 ±8 .5  
(21-42)
27.8 ±3 .7  
(24-34)
Body
Weight
(kg)
60.2 ±5 .4  
(51.4-69.8)
60.4 ±7 .6  
(49-76.1)
64.6 ± 10.0 
(54.5-77.2)
Height
(cm)
163.0 ± 5.2 
(152-171)
165 ± 5.9 
(156-180)
166 ±7.1 
(152-173)
BMI
(kg/m2)
22.6 ± 2.3 
(19.6-27.4)
22.1 ±2 .0  
(18.9-27.0)
23.3 ± 2.5 
(19.9-25.9)
BSA
(m2)
1.8 ±0.11 
(1.70-2.09)
1.8 ±0.15  
(1.71-2.21)
1.9 ±0.20  
(1.77-2.23)
Values are means ± SEM (range);
No statistically significant differences were found among groups 
BMI = Body Mass Index 
BSA = Body Surface Area
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Experimental Procedures
Volunteers were recruited by word of mouth, flier advertisement, and 
physician referral. Preliminary screening by telephone confirmed inclusion and 
exclusion criteria. If the subject was deemed appropriate for the study, and was 
still interested in participating, a meeting was scheduled for the purpose of 
explaining the study’s requirements in detail, signing the informed consents, and 
completing the physical fitness testing to be used in the Physical Fitness Profile 
(PFP). The PFP was provided to each subject as an incentive to participate in the 
study and was not included in the data collection. The sequence of this preliminary 
testing was as follows:
1) Determination of body weight and height, using upright scales (Health-0- 
meter, Baumann), and calculation of BMI (kg/mz);
2) Determination of body fat from the sum of three skinfold measurements 
(suprailium, thigh, and triceps) using Lange Skinfold Calipers; standard values 
used to determine fitness level were those of The Institute for Aerobics Research 
in ACSM’s Guidelines for Exercise Testing and Prescription, 5th Edition, 1995, p. 
112;
2) Muscular strength determined by 1 repetition max (1RM) tests on the 
Nautilus leg press machine and the Body Masters bench press; standard values 
used to determine fitness levels were those of The Institute for Aerobics Research 
in ACSM’s Resource Manual for Guidelines for Exercise Testing and Prescription, 
2nd Edition,1993, p.241;
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3) Flexibility determined by sit-and-reach test; standard values used to 
determine fitness level were those of The Institute for Aerobics Research in 
ACSM’s Guidelines for Exercise Testing and Prescription, 5th Edition, 1995, p. 
128;
4) Lung function determined by spirometry: FEV1/FVC (Pneumoscan S-300 
Spirometer);
5) Resting 12-lead electrocardiogram, reviewed by a board-certified 
cardiologist;
6) Dual Energy X-ray Absorptiometry (DEXA) for determination of bone 
density of the lumbar spine and proximal femur using QDR-1000 (Hologic, 
Waltham, MA);
7) Nutritional assessments were performed using Nutritionist IV computer 
software, Version 4, First DataBank;
Subjects were then scheduled to perform the submaximal cycle ergometer 
test to be performed either during their menses (day 1-4) or during the follicular 
phase (day 8-12) whichever came first and was convenient. They were advised
•  to abstain from food and drink (other than water) after midnight the 
evening before testing
•  to avoid moderate or vigorous physical activity within 12 hours of the
test
•  to empty bladder prior to testing
•  to abstain from alcohol consumption within 48 hours of the test
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•  to ingest no over-the-counter drug, eg., aspirin, ibuprofen, or 
decongestant, etc., within 24 hours of the test.
Equipment used in the cycle ergometer test were the QMC™ metabolic cart 
(Quinton Instrument Co., Bothell, WA.), Quinton electronically braked cycle 
ergometer analog, and Quinton electrocardiogram heart rate analog.
Before each test, the QMC™ metabolic cart’s power and analyzer switches 
were turned on and allowed to warm up for thirty minutes before calibrating the 
pneumotach and 0 2 and C 02 gas analyzers with standard grade gas mixtures, 
according to manufacturer’s instructions. The room environment was kept 
constant during the study period: 72 °F (22.2°C), ~50% humidity.
Upon arrival at the testing laboratory at 7:00 a.m. the subject was prepped 
for the placement of 5 electrodes (LL, LA, RL, RA, and Vs) for a continuous 
monitor of electrocardiogram and heart rate analog input. Resting blood pressure 
was measured by auscultation, using a mercury sphygmomanometer on a rolling 
base. The subject was given instructions on how to breathe through the 
mouthpiece. The headgear and nose clip were placed on the subject, and she 
was asked to sit quietly in a chair with her legs elevated in the semi-Fowler 
position. After 15 minutes of resting data collection, the headgear, mouthpiece, 
and nose clip were removed, and a catheter was inserted into an antecubital vein 
in the arm with a stopcock in the line and a 50 cc bag of normal saline set at a 
keep-open rate. The first blood sample (baseline) was collected at this time.
The subject was then asked to sit on the cycle ergometer in order to set 
seat height (5-20 degrees flexion). The breathing apparatus was re-attached, and
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the subject was asked to begin pedaling at 50 RPM’s at zero resistance (zero 
watts). After two minute stages, the workload was increased by 10 watt 
increments, and this was continued every 2 minutes until 60% of the age-predicted 
maximal heart rate (220 - age x 60%) was achieved (60%HR). Blood pressure 
and rating of perceived exertion (RPE using Borg scale 6-20) were documented 
at each stage. At 10 minutes the second blood sample was drawn. Upon 
reaching 60%HR, the subject was asked to continue pedaling at 50 RPM’s for the 
remainder of the 20 minute test Workload was continually assessed and changed 
to maintain steady state at the 60% goal. The third blood sample was drawn at 
the conclusion of the work test (20 minutes). Indications for stopping the tests 
were the following ( ACSM Guidelines, 1995):
1. Onset of angina or angina-like symptoms
2. Significant drop (20 mm Hg) in systolic 
blood pressure or a failure of the systolic 
blood pressure to rise with an increase in 
exercise intensity
3. Excessive rise in blood pressure: systolic 
pressure >260 mm Hg or diastolic pressure 
>115 mm Hg
4. Signs of poor perfusion: lightheadedness, 
confusion, ataxia, pallor, cyanosis, nausea, or 
cold and clammy skin
5. Failure of heart rate to increase with 
increased exercise intensity
6. Noticeable change in heart rhythm
7. Subject requests to stop
8. Physical or verbal manifestations of severe 
fatigue
9. Failure of the testing equipment
The mouthpiece, noseclip, and supporting headgear were removed 
immediately after testing, and the subject was asked to cool down gradually, still
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pedaling at a slow rate, with no workload. The catheter and IV were then removed 
and the subject was offered oral fluids.
Indirect Calorimetry
As opposed to direct calorimetry which is the measurement of heat 
production as a result of energy expenditure, indirect calorimetry measures the 
rate of oxygen uptake or oxygen consumption (VOJ. Taken alone, V 02 provides 
a measure of the amount of energy expended (ACSM, 1995). When combined 
with concurrent measurements of carbon dioxide production (VC02), oxygen 
consumption provides information about the type of fuel being used, e.g., fat or 
carbohydrate.
In this study, respiratory gases were collected and analyzed using open 
spirometry on a breath-by-breath basis, and averaged over 30 second periods, 
using the QMC™ Software, version 2.10. Volume of air breathed, minute 
ventilation (VE), was reported in liters per minute (L/min), volume of oxygen 
consumed was reported in absolute terms (L/min) and relative terms (ml/kg/min). 
The volume of carbon dioxide produced was reported in liters per minute.
The R value was calculated and reported by the QMC using the ratio of 
VC02/V02. Table 3.2 is the culmination of detailed research performed by early 
investigators in the field of nutrition and metabolism. It depicts the range of R 
values from 0.707 representing no oxygen being consumed by carbohydrate and 
all of the oxygen being consumed by fat, utilizing 4.686 calories per liter of oxygen, 
to a value of 1.00, representing 100% oxygen being consumed by carbohydrate, 
no oxygen being consumed by fat, and utilizing 5.047 calories per liter of oxygen.
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Table 3.2. Analysis of the Oxidation of Mixtures of Carbohydrate and Fat
R.Q. P erce n tag e  o f to ta l oxygen 
con sum ed b y :
P e rce n ta g e  o f to ta l he a t 
(C a lo rie s ) p ro d u ce d  by.
C a lo rie s  p e r lite r 0 ,
C a rb o h yd ra te F a t C a rb o h yd ra te F a t N um ber Lo ga rith m
0.707 0 100.0 0 100.0 4.686 0.67080
0.71 1.02 99.0 1.10 98.9 4.690 0.67114
0.72 4.44 95.6 4.76 95 2 4.702 0.67228
0.73 7.85 9 2 2 8.40 91.6 4.714 0.67342
0.74 11.3 88.7 120 88.0 4.727 0.67456
0.75 14.7 85.3 15.6 84.4 4.739 0.67569
0.76 18.1 81.9 192 80.8 4.751 0.67682
0.77 21.5 78.5 22 8 77 2 4.764 0.67794
0.78 24.9 75.1 26.3 73.7 4.776 0.67906
0.79 28.3 71.7 29.9 70.1 4.788 0.68018
0.80 31.7 68.3 33.4 66.6 4.801 0.68129
0.81 3 5 2 64.8 36.9 63.1 4.813 0.68241
0.82 38.6 61.4 40.3 59.7 4.825 0.68352
0.83 42 0 58.0 43.8 56 2 4.838 0.68463
0.84 45.4 54.6 4 7 2 528 4.850 0.68573
0.85 48.8 51 2 50.7 49.3 4.862 0.68683
0.86 5 2 2 47.8 54.1 45.9 4.875 0.68793
0.87 55.6 44.4 57.5 4 2 5 4.887 0.68903
0.88 59.0 41.0 60.8 39 2 4.899 0.69012
0.89 6 2 5 37.5 64 2 35.8 4.911 0.69121
0.90 65.9 34.1 67.5 3 2 5 4.924 0.69230
0.91 69.3 30.7 70.8 2 9 2 4.936 0.69339
0.92 72 7 27.3 74.1 25.9 4.948 0.69447
0.93 76.1 23.9 77.4 22 6 4.961 0.69555
0.94 79.5 20.5 80.7 19.3 4.973 0.69663
0.95 82 9 17.1 64.0 16.0 4.985 0.69770
0.96 86.3 13.7 8 7 2 128 4.998 0.69877
0.97 89.8 10 2 90.4 9.58 5.010 0.69984
0.98 9 3 2 6.83 93.6 6.37 5.022 0.70091
0.99 96.6 3.41 96.8 3.18 5.035 0.70197
1.00 100.0 0 100.0 0 5.047 0.70303
Source: Lusk, G. The Elements of the Science of Nutrition, 4th Ed., 1976, p.65
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See Rgure 3.1. for formulas used to obtain these values. The percentage of total 
heat produced (kilocalories) by carbohydrate (%CHO) and the number of 
kilocalories expended per liter of oxygen (kcal/LOj) were computed by SAS using 
these formulas. Using simple linear regression of percent carbohydrate utilization 
at workloads of 10,20,30, and 40 watts, the crossover points were established for 
each subject and then averaged for each group.
Analysis of Blood Samples
Three sets of blood samples of approximately 20 ml each, were withdrawn 
from the stopcock system and placed in a 20cc glass test tube. A microcapillary 
tube was immediately filled and set aside for analysis after the test. Approximately 
two ml of whole blood was also placed into a green-topped vacutainer containing 
sodium heparin to be used to analyze for plasma ammonia, lactate and glucose, 
and 0.5 ml was placed in two ml chilled perchloric acid for possible use in later 
serum analyses. The remaining blood was allowed to coagulate in the large 
collection tube. All tubes were placed on ice until the completion of the test. The 
tubes were then centrifuged at 10,000 RPM for 10 minutes, and alliquots of the 
plasma and serum were placed into labeled glass test tubes. Samples were 
placed in a -80 degrees centigrade freezer for future analysis. A sample was sent 
to the lab for analysis of lipids on the same day as testing. Each type of assay 
was performed on all samples on the same day, and with kits using the same lot 
numbers, to avoid interassay variations. Also, all samples were thawed only once 
for each assay procedure. Hematocrit was measured using microcapillary tubes 
centrifuged at 11,000 for 5 minutes within 15 minutes after testing.
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Percentage (%) of total oxygen consumed by 
carbohydrate =100 [(R  - 0.707) /  0.293]
Percentage (%) of total oxygen consumed by fat 
= 100 [(1.00 - R) /  0.293]
Percentage (%) of total heat produced (Calories 
expended) by carbohydrate = {[504.7 (R - 0.707)] / 
[5.047 (R - 0.707) + 4.686 (1.00 - R)]}
Percentage (%) of total heat produced (Calones 
expended) by fat = {[468.6 (1.00 - R)] /
[5.047 (R- 0.707) + 4.686 (1.00 - R)]}
Calories (C) per liter oxygen =
4.686 + [(R - 0.707) /  0.293] * 0.361
The logarithm of Calories =  log of the number of 
Calories calculated above
Figure 3.1. Formulas used to derive mixtures of carbohydrate and fat 
utilization. (Refer to Table 3.1)
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Levels of serum total cholesterol (TC), HDL cholesterol, and triglycerides 
(TRIG) were measured directly by colorimetry using the automated Vitros 700 
Analyzer and Vitros CHOL Slides, Vitros HDL Cholesterol Kit, and TRIG Slides, 
respectively (Johnson & Johnson Clinical Diagnostics, Inc., Rochester, NY). The 
method for measuring TC is based on an enzymatic method similar to that 
proposed by Allain and associates (1974). The method for measuring HDL is 
described previously (Wamick, etal., 1983). The method for measuring TRIG is 
based on an enzymatic method as described by Spayd and associates (1978). 
Within lab precision (Coefficient of Variation = CV%) was determined to be 1.5-4.1 
for TC, 1.5-4.4 for HDL, and 1.4-1.9 for TRIG. Sensitivity (the lower limit of the 
reportable, dynamic range) was 50 mg/dl for TC, 0.1 mg/dl for HDL, and 10.0 
mg/dl for TRIG. LDL cholesterol levels were calculated using the formula: LDL 
= Total Cholesterol - [HDL + (Triglyceride/5)] according to Tietz (1990).
Estradiol levels in the blood were measured using an automated 
immunoassay analyzer (IM®x Abbott Diagnostics, North Chicago, IL) and 
Microparticle Enzyme Immunoassay (MEIA) technology. The estradiol kit was 
obtained from Abbott Laboratories (Diagnostics Division, Abbott Park, IL 60064). 
The sensitivity of the Imx Estradiol assay was previously calculated to be 15 pg/ml 
(the lowest measurable concentration of estradiol that can be distinguished from 
zero). The coefficients of variation (%CV’s) for within assay, between assay and 
total assay precision were determined to be 10.4,16.0, and 19.1 respectively, for 
mean value of 67; %CV’s = 6.3,6.7, and 9.2 for mean value of 140; %CV’s = 3.8,
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4.3, and 5.7 for mean value of 524; and %CVs = 4.1,4.5, and 6.1 for mean value 
of 1166 (Krouwer & Rabinowitz, 1984).
Plasma glucose (GLU), ammonia (AMON or NH3), and lactate (LAC) were 
determined by colorimetry, using the automated Vitros 700 Analyzer and Vitros 
GLU Slides, AMON Slides, and LAC Slides, respectively (Johnson & Johnson 
Clinical Diagnostics, Inc., Rochester, NY). The dye system used in measuring 
GLU is related to that reported by Trinder (1969), and the chemistry of the 
glucosed slides used has previously been described (Curme, et al., 1978). The 
reaction sequence used in the measurement of AMON is: NH3 + bromophenol 
blue— >blue dye (spectrophotometrically measured at 600 nm). The reaction
sequence used in the measurement of LAC is: L-(+)-lactic acid + 0 2 lactate
oxidase >pyruvate + H20 2---------------- >2 H*Q, + 4-aminoantipyrine + 1,7-
dihydroxynaphthalene— peroxidase—>red dye (spectrophotometrically measured 
at 540 nm). Within lab precision was previously determined to be 1.0-1.7 CV% for 
GLU, 1.6-10.8 CV% for AMON, and 1.3-1.8 CV% for LAC, respectively. Sensitivity 
was previously determined to be 20.0 mg/dl for GLU, 1.0 pmol/L for AMON, and 
4.51 mg/dl for LAC.
Serum cortisol was measured by Fluorescence Polarization Immunoassay 
(FPIA) using the automated TDx™ analyzer and the TDx/TDxFLx cortisol assay 
reagent system (Abbott Laboratories Diagnostics Division, Abbott Park, IL). 
Sensitivity was previously determined to be 0.64 pg/dl (Abbott Laboratories).
Serum insulin was determined by MEIA using the !M®x automated 
immunoassay analyzer and IM®x insulin reagents (IM®x Abbott Diagnostics, North
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Chicago, IL). The %CV,s for within assay, between assay, and total assay 
precision were all less than 6.0 (Krouwer & Rabinowitz, 1984).
Experimental Statistics and Design
Resting and exercise data were entered as separate tests for each subject. 
Data were depicted descriptively and outliers (>2 standard deviations from group 
mean) eliminated before inferential statistics were applied. Microsoft EXCEL for 
windows, v7.0, was used to convert the QMC™ ASCII files to SAS® files (SAS 
System for Windows™ v 6.12; Cary, NC); GB Stat for Windows, v 5.0 (Dynamic 
Microsystems, Inc., Friedman, 1993), and SAS® were used for descriptive 
analyses and statistical procedures. Significance was set a priori at p<0.10. 
Tukey’s post hoc tests were performed when significance was found. Unless 
otherwise stated, results are reported as means ±  SD. A post hoc power analysis 
was performed on the criterion R values which resulted in <J> = 0.90.
Mean values of the dependent variables of the three groups, M, F, and G 
(eumenorrheic @ menses, eumenorrheic @ follicular, and hypoestrogenemic due 
to GnRHaa therapy, respectively) were compared during rest, during each stage 
of exercise (0, 10, 20, 30, 40 Watts) and during the last 5 minutes of exercise 
using a one way analysis of variance (ANOVA). Multiple regression analysis was 
also used in an effort to fully describe the proportion of variability in the R value 
derived from estrogen level, BMI, and age.
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CHAPTER 4. RESULTS
Results of data collection are divided into 5 separate studies: (1) at rest; (2) 
at absolute workloads, after 2 minutes of freewheeling warmup (denoted as 0 
watts, herein) of 10,20,30, and 40 watts; (3) at steady-state of 60% age-predicted 
maximum heart rate; (4) blood analyses; and (5) crossover point analysis . Data 
in the rest and exercise studies are further delineated by cardiorespiratory and 
metabolic parameters. Data are presented in tabular form as group means ± 
standard deviation, as well as in graphic form. Significance is denoted with a 
superscript and foot-noted. Refer to the Appendix for individual results.
Resting Study
The resting portion of the study comprised of 15 minutes of data collection, 
of which the first two minutes were eliminated due to the number of outliers. There 
were no significant differences found among groups for the cardiorespiratory 
variables of VE, absolute V 0 2 and VC02. However, group G demonstrated the 
smallest relative V 0 2, differing significantly from group M (p=0.0395). Group G 
also demonstrated a lower resting heart rate (HR) than both group F (p=0.0415) 
and group M (p=0.0549), as well as a lower percentage age-predicted HR (%HR) 
than group F (p=0.0344) and group M (p=0.0332). (Refer to Table 4.1.)
There were no significant differences among group means for the metabolic 
variables (Table 4.2): R, %CHO/FAT utilized, kilocalories expended per liter of 
oxygen (kcal/O^, kilocalories expended per minute (kcal/min), and resting energy 
expenditure per day (REE) in kilocalories.
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Table 4.1. Group Means of Cardiorespiratory Variables at Rest
Variable Group M Group F Group G
V 0 2stpd (L/min) 0.15 ±0.03 0.14 ±0.03 0.12±0.03
V 0 2 (ml/kg/min) 2.54±0.50 2.11 ±0.40 1.79±0.70 8
V C 02stpd (L/min) 0.14±0.02 0.13±0.04 0.10±0.02
VEbtps (L/min) 4.10±1.70 3.33±1.36 3.07±1.50
HR (BPM) 74.0± 8.2 76.0± 10.3 62.6± 8 .4 b
%HRmax 39.1 ±4.2 39.8±5.5 32.5±4.2C
Values are mean ± standard deviation.
8 Different from Group M (p=0.0395)
b Different from Group F (p= 0.0415) and Group M (p=0.0549).
c Different from Group F (p=0.0344) and Group M (p=0.0332).
Table 4.2. Group Means of Metabolic Variables at Rest.
Variable Group M Group F Group G
R 0.883 ± 0.06 0.891 ± 0.074 0.89 ±0 .08
%CHO 61.8 ±21.03 64.5 ± 24.76 64.9 ±  25.00
kcal/L02 4.90 ± 0.08 4.91 ± 0.09 4.91 ±  0.09
kcal/min 0.78 ±0.17 0.72 ±0.19 0.61 ±0.17
REE(kcal/day) 1122.00 ±247.68 1039.81±270.77 870.28±240.56
Values are mean ± standard deviation.
No Significant Differences among means.
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Graded Workload Study
Variable responses were analyzed at the second minute of each stage after 
2 minutes of freewheeling at 0 watts, i.e., second minute at 10, 20, 30 and 40 
watts. There were no differences among groups for most of the cardiorespiratory 
variables. The two exceptions were (1) group G had a significantly lower VE at 
40 watts than group M (p=0.0684), and (2) during the 10 watt workload, %HR for 
group G was lower and dose to significance (group F: p=0.0525 and group M: 
p=0.0933). There were no significant differences among group means for the 
metabolic data. Refer to Tables 4.3 and 4.4.
Steadv-state Study
After 10 minutes of graded exercise (increasing workloads), the next 5 
minutes were allowed to achieve steady state at 60% of age-predicted maximum 
HR, and then the variable response was analyzed for the last 5 minutes of 
exerdse. No significant differences were found among group means for either the 
cardiorespiratory or metabolic variables measured. Refer to Tables 4.5 and 4.6. 
Total Work
Group G differed also in the amount of work performed during exercise at 
steady state. The group had a significantly higher power output in watts, differing 
from group F (p=0.0006) and group M (p=0.0026), and in kilopond meters (KPM’s), 
differing from group F (p=0.0020) and group M (p=0.0029). Refer to Table 4.7.
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Table 4.3. Summary of Group Means of Cardiorespiratory Variables
at 0,10, 20, 30, and 40 Watts.
VARIABLE Watts GROUP M GROUP F GROUP G
VOjStpd 0 0.22±0.05 0.2510.06 0.2410.04
(L /m in ) 10 0.25±0.06 0.2610.06 0.2610.06
20 0.30±0.05 0.2810.07 0.3110.07
30 0.3810.05 0.3610.08 0.3510.10
40 0.5110.07 0.5010.08 0.46 0.131
V 0 2 0 3.710.8 4.U 1.3 3.810.8
(m l/kg) 10 4.211.0 7.7H7.6 3.911.4
20 4.910.9 4.911.3 4.811.1
30 6.411.1 6.111.3 5.511.5
40 8.611.6 8.511.4 7.311.9
VCOjStpd 0 0.1710.04 0.1910.05 0.1910.03
(L/m in) 10 0.2010.05 0.2010.05 0.2010.05
20 0.2410.04 0.2310.06 0.2510.06
30 0.3310.05 0.3110.07 0.2910.09
40 0.4710.08 0.4510.08 0.4010.12
VEbtps 0 5.5811.8 4.7112.1 5.1312.7
(L/min) 10 6.8911.8 5.91i2£ 5.3712.8
20 8.5911.8 7.0912.6 7.1412.9
30 11.50l2£ 9.9112.4 9.0013.2
40 15.5613.2 13.6012.9 12.1213.7*
HR 0 89.318.0 90.218.5 82.918.4
(BPM) 10 94.619.3 94.619.3 85.718.0
20 98.218.0 98.5110.3 91.918.5
30 106.818.2 106.519.7 98.6110.1
40 117.8111.3 116.5111.2 107.619.3
%HRMAX 0 47.214.2 47.614.1 43.214.2
10 49.614.2 49.814.4 44.614.0 *
20 51.814.0 51.615.0 47.814.1
30 56.214.2 56.115.0 51.315.1
40 62.016.0 61.315.8 56.214.8
Values are mean ± standard deviation.
8 Different from Group M (p=0.0684). 
b Different from Group F (p=0.0525) and Group M (p=0.0933).
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Table 4.4. Summary of Group Means of Metabolic Variables
at 0,10,20, 30, and 40 Watts.
VARIABLE Watts GROUP M GROUP F GROUP G
R 0 0.76±0.06 0.7540.06 0.78 40.05
10 0.81 40.04 0.7940.05 0.79 40.04
20 0.8340.04 0.8040.05 0.80 40.03
30 0.8740.06 0.8440.08 0.8340.03
40 0.9240.08 0.90 40.07 0.9240.03
%CHO 0 20.97422.3 16.31419.2 28.30418.1
10 36.71414.6 26.42421.0 28.57417.1
20 44.34414.3 31.82420.6 35.74413.6
30 58.14421.1 48.21421.7 44.68412.1
40 72.56424.4 63.71424.3 59.55410.23
kcal/LO, 0 4.7540.07 4.7440.06 4.7840.06
10 4.8140.05 4.7740.07 4.7840.06
20 4.8440.05 4.7940.07 4.8040.04
30 4.8940.07 4.8540.07 4.8440.04
40 4.9440.09 4.9140.08 4.8940.03
kca l/min 0 1.0540.22 1.1540.37 1.0740.26
10 1.1540.36 1.2740.46 1.3040.48
20 1.4540.51 1.4540.51 1.5040.51
30 1.9040.30 1.8140.58 1.5740.51
40 2.5040.51 2.5440.50 2.2840.72
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table 4.5. Group Means of Cardiorespiratory Variables at 60 % Age-predicted
Maximum Heart Rate (Last 5 Minutes of Exercise)
VARIABLE GROUP M GROUP F GROUP G
V 0 2 stpd (L/min) 0.46±0.19 0.43±0.18 0.51*0.15
V 0 2 (ml/kg) 7.64±3.11 7.52±3.32 8.10*2.27
VCOz (L/min) 0.41 ±0.17 0.39±0.19 0.46*0.14
VEbtps (L/min) 13.82±5.30 12.34*4.59 14.37*3.82
HR (BPM) 116.37±4.90 118.67±5.57 118.48*3.43
%HRMAX 61.41*1.66 61.9*1.66 61.78*1.32
Values are mean *  standard deviation.
No Significant Differences among group means.
Table 4.6. Group Means of Metabolic Variables at 60% Age-predicted 
Maximum Heart Rate (Last 5 minutes of exercise)
VARIABLE GROUP M GROUP F GROUP G
R 0.891 *0 .0 4 0.888 *  0.06 0 .908*0 .03
%CHO 64.39 *  15.79 63.2 *  16.82 70.11 ±12.12
kcal/L02 4.91 *  0.05 4.91 *  0.06 4.93 *  0.04
kcal/min 2.28*1.05 2.11*0.94 2 .5 5 *0 .7 6
Values are mean ± standard deviation.
No Significant Differences among group means.
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Blood Analysis
Estrogen status was confirmed, and as expected, groups M (p<0.05) and 
G (p<0.01) were significantly lower than group F. Refer to Table 4.8 for results 
of blood analysis data and Figure 4.1 for a graphic representation of estrogen 
status at rest. There were no significant differences among group means for 
cortisol, glucose or hematocrit. Some differences were found within groups, 
however, in the remaining metabolic substrates of lactate and ammonia. Resting 
values were lower than the exercise values for ammonia in group M (p<0.05), 
and for lactate in group F (p<0.05) and group M (p<0.01).
Crossover Points
The crossover point was estimated to be 30.8 (±25.44) watts for group M, 
34.79 (±26.53) watts for group F, and 32.85 (±7.33) watts for group G. The 
differences were not statistically significant. Refer to Table 4.9.
Diet Analysis
An analysis of the 24 hour food intake prior to testing revealed no significant 
differences among groups for total kilocalories consumed, percent of kilocalories 
in the macronutrients of fat (%Fat), protein (%Pro), or carbohydrates (%CHO). 
Refer to Table C.1 in the Appendix for individual values and means per group. 
Multiple .Regression Analysis
Multiple regression was performed and revealed no significant contribution 
of estrogen status, BMI, or age to the R value.
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Table 4.7. Group Means of Work Performed During Submaximal 
Ergometer Test at settings of 0 ,1 0 ,2 0 , 30,40 Watts 
and @ 60% Age-Predicted Maximum Heart Rate 
in Watts and KPMs.
Work Settings Group M Group F Group G
Watts 0 0.5010.51 0.7710.50 0.3510.49
10 10.4010.59 10.4010.50 10.4010.50
20 20.2010.41 20.3610.56 20.2110.42
30 30.5010.51 31.2512.56 30.57t0.51
40 40.2510.44 39.9613.99 40.0010.00
60% 31.24112.87 30.83114.27 37.8518.36
KPMs 0 3.210.69 3.4711.70 2.6410.84
10 63.7512.82 63.6912.89 63.6912.89
20 124.6512.56 124.0912.94 123.85l2.56
30 185.611.66 191.52116.71 186.0711.77
40 246.5512.35 245.08125.90 245.78t1.36
60% 190.98179.31 190.40194.47 232.34150.54
Values are mean ± standard deviation.
No Significant Differences among means.
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Table 4.8. Group Means of Blood Analyses.
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Time of Draw Group M Group F Group G
Estrogen
(pg/ml)
@Rest (0) 56.43± 27.4 • 217.31 ±236.25 7.31±6.98 b
Total
Cholesterol
(mg/dl)
@Rest (0) 158.5±15.1 169.4 ±27.6 160.6±33.6
HDL (mg/dl) @Rest (0) 48.3 ±13.0 56.5 ±7.6 53.5 ±8.0
LDL (mg/dl) @Rest (0) 91.8 ±12.7 99.2 ±21.9 93.9 ±29.0
Triglycerides
(mg/dl)
@Rest (0) 92.0 ±71.2 68.5 ±22.9 66.0 ±28.1
Glucose 0 86.8 ±4.4 82.4 ±12.5 90.1 ±10.4
(mg/dl) 10 86.0 ±5.3 85.0 ±8.1 91.8 ±9.1
20 83.8 ±7.3 82.3 ±14.0 90.5±9.5
Ammonia 0 18.6 ±6.2 c 25.2 ±11.9 24.6 ±7.3
(pmol/L) 10 22.0 ±5.4 28.5 ±16.6 32.6 ±10.4
20 25.5 ±5.8 36.3 ±31.1 34.5 ±10.5
Lactate 0 1.1 ±0.3 1.1 ±0.3 d 1.0 ±0.2*
(mmol/L) 10 1.9 ±1.0 1.9 ±0.8 1.9 ±0.2
20 1.8 ±1.2 2.2 ±1.1 1.9 ±0.2
Cortisol 0 14.13 ±4.76 16.82 ±6.88 14.34 ±2.88
(M9/dl) 10 13.58 ±4.85 17.09 ±5.99 13.78 ±3.91
20 12.09 ±4.66 16.42 ±4.71 13.40 ±3.81
Values are mean ± standard deviation.
■ Different from Group F (p<0.05). 
b Different from Group F (p<0.01). 
c Different from Within group @20 (p<0.05). 
d Different from Within group @10 (p<0.01) and @20 (p<0.05). 
* Different from Within group @10 and @20 (p<0.01).
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Figure 4.1. Serum Estrogen Levels of All Subjects at Rest (pg/ml)
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Table 4.9. Calculated Crossover Points of Subjects (Watts)
Subject Group M Group F Group G
1 6.47 48.69 27.47
2 18.98 42.63 40.31
3 18.74 26.75 43.57
4 29.19 25.56 27.91
5 5.71 31.95 24.91
6 42.00 53.54 28.67
7 42.94 38.65 37.14
8 22.55 50.15
9 93.75 101.28
10 27.65 23.10
11 12.99
12 39.16
13 -11.44
14 4.07
Group Mean±SD 30.80±25.44 34.79±26.53 32.85±7.33
No Significant Differences among group means.
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CHAPTER 5. DISCUSSION
The main purpose of this study was to examine the influence that estrogen 
status, i.e., chronically low, acutely low and acutely high concentrations as found 
in postmenopausal, menses and follicular phase, has on fuel substrate utilization 
at rest, and at specific absolute and relative submaximal workloads.
During the resting metabolic and cardiorespiratory studies, the three groups 
demonstrated little variation among their V 02 (l/min) and R means. Since the 
other resting metabolic variables, %CHO, kcal/L02, kcal/min and REE were all 
based on the R value, significant differences would not be expected. While no 
differences were found in absolute oxygen consumption, there was a significant 
difference found in the relative oxygen consumption: Group G was significantly 
lower than group M, but not group F. These results are directly influenced by the 
weight of the subjects, i.e., given the same absolute oxygen consumption, the 
heavier individuals will have a lower relative oxygen consumption. Even though 
there were no significant differences found among the average body weights of the 
groups, group G was heaviest (p=0.4263). The lowest absolute oxygen 
consumption coupled with the highest body weight probably led to the significant 
difference in relative oxygen consumption.
The R value of group G was one point (0.01) higher than that of the other 
two groups, but was nevertheless insignificant. Kanaley and associates (1992) 
corroborates these findings. They tested two groups of women athletes, one 
eumenorrheic group (n=7) which was tested three times-at the early follicular 
phase, late follicular phase, and the mid-luteal phase of their menstrual cycles,
50
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and compared the results to an amenorrheic group (n=6). Even though their 
findings were not significant, higher R values were found for the amenorrheic and 
early follicular subjects compared to the late follicular (and luteal) subjects at rest 
They nevertheless concluded that resting carbohydrate and fat utilization were not 
affected by phase-related differences in estrogen.
With respect to the other resting variables, heart rate and percentage of 
age-predicted maximum heart rate were significantly different among groups. 
Group G responded with lower values when compared with the other two groups. 
There are conflicting results from earlier studies regarding heart rate response 
during different phases of the menstrual cycle. An early study reported that heart 
rate was lower during the menses than during other phases (Cullis, et al, 1922). 
Phillips (1966), however, reported that menstrual cycle phases did not have an 
effect on pulse rate. Differences in resting heart rate might be explained by higher 
fitness levels, but this factor probably is not the reason for the differences seen in 
this study since a screening process was used to ensure that the participants had 
similar activity levels. Moreover, it seems likely that if they were more fit, they 
would have responded with lower heart rates at any workload, but their response 
to increased workloads in the graded portion of the test were similar to those in the 
other groups. Another possible reason that differences were seen in resting HR 
is that group G was slightly larger in body size, and hence decreased HR could be 
due to group G having a slightly larger stroke volume. It is also possible that the 
resting portion of the study was not a long enough period of time to elicit true 
resting heart rate values. It is interesting to note that no studies have investigated
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the effects of GnRHaa on resting HR. It has been reported by TAP 
Pharmaceuticals, Inc. (1997) that side effects of GnRHaa therapy include a small 
percentage of patients presenting with tachycardia and palpitations and no reports 
of depressed heart rajfc per se. Therefore, the possibility of GnRHaa being a 
cardiodepressive cannot be discounted, but it is unlikely.
It is important to note that even though there was no statistical significance 
between metabolic variables, a small difference could have considerable 
consequences over a period of time. The long term effects of the small metabolic 
differences, as shown in the results of this study, can be easily calculated. For 
instance, if a sedentary premenopausal female has been consuming a 1500 kcal 
diet and maintaining her weight, it is assumed that her energy expenditure is 
approximately equal to 1500 kcal. Her basal or resting energy expenditure would 
be 1039.81 kcal (based on group F resting values), with the remaining 460.19 kcal 
attributed to light daily activity. Now assuming she has become postmenopausal 
and that her activity (460.19 kcal) and her energy consumption (1500 kcal) have 
not changed, her resting energy expenditure would drop to approximately 870.28 
kcal (group G value at rest). Now, when her resting energy expenditure is added 
to her normal unchanged activity of 460.19 kcal, the total caloric expenditure is 
1330.47 kcal, 169.53 kcal less than the premenopausal daily expenditure. Hence, 
over a 30 day period, she would consume approximately 5086 kcal more than her 
maintenance weight would require. Since one pound of fat is equal to 3500 kcal, 
it is conceivable that once a woman reached menopause, she could gain 
approximately 1.45 pounds of fat weight per month totaling about 17 pounds in
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one year. Of course, a woman does not normally jump from premenopause to 
postmenopause overnight. It is a transition over a period of months and even 
years. So any weight gain due to a decreased resting expenditure would be a 
gradual phenomenon, and noticeable only after a period of months. Hence, an 
acute study may not be the most appropriate model to investigate the influences 
of estrogen. A prolonged longitudinal study would need to be employed to 
document the alteration in body composition suggested above.
During the graded workload study, all three groups again responded 
similarly in both the metabolic study and the cardiorespiratory study. There were 
two anomalies, with group G responding with a lower minute ventilation than group 
M only at 40 watts, and the same group responding with a lower %HR than group 
M and group F only at 10 watts. According to this study’s protocol, workload was 
begun at zero watts for two minutes as a warmup and then workload was 
increased by 10 watts every 2 minutes (until -5 0  watts). The rate with which work 
is incremented can have a profound influence on oxygen uptake and, moreover, 
individuals vary considerably in their ability to adapt to a given workload 
(Gullestad, etal., 1997). Statistically significant differences have been found in R 
between 1 minute and 3 minute stages on a cycle ergometer when increases are 
between 40 and 70 watts (Gullestad, etal., 1997). It is desirable to reach steady 
state at each stage, that is, to allow time for respiration and circulation to adjust to 
the new intensity. At steady state, oxygen uptake corresponds to the demands of 
the tissues (oxygen uptake = oxygen requirement), and carbon dioxide production 
is stabilized. Otherwise, true metabolic status cannot be measured. According
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to Astrand & Rodahl (1986), a stage of at least 5 minutes is required to obtain 
steady state conditions. In this study, even though the incremental workloads were 
very small compared to other submaximal cycle ergometer protocols, and steady 
state was expected to occur, it is likely that the two minute stages were not long 
enough to elicit steady state in this untrained population and thus hindered the 
detection of metabolic differences.
No significant differences were found among group means at steady state 
exercise and therefore the results of this study do not support the hypothesis that 
there would be differences. There are several possible reasons for the lack of 
significance. The extremely low oxygen consumption values, even during 
exercise, were surprising. However, they were substantiated using the metabolic 
formula for oxygen consumption for the cycle ergometer in the ACSM’s Guidelines 
for Exercise Testing and Prescription (1995). These findings thus confirmed that 
the overall fitness of the subjects was poor and supported the inclusion criteria of 
the subjects prior to testing. Even though this study was designed to study rest 
and “moderate” exercise response at absolute workloads and a relative intensity 
of 60% of age-predicted maximum heart rate of untrained women, there may have 
been enough difference in fitness levels to cause problems in the comparisons of 
the group averages. Obtaining a peak V 02 on subjects, and adding a relative 
intensity, i.e., @ 60% peak V 0 2, to the protocol might have provided more 
information. However, other studies have found that carbohydrate and fat 
utilization during exercise at 60% peak V 02 were not influenced by levels of 
estrogen associated with menstrual phases (Kanaley, etal., 1992).
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There is no doubt that GnRHaa therapy does cause estrogen status to drop 
to menopausal levels, and even causes menopausal symptoms. It is, therefore, 
a good postmenopausal model. Also, since the estrogen drop is so large, it can 
be assumed that the results of this study are based on this predominant factor. 
However, it must also be considered to be a limitation of the study design because 
there may be inherent problems associated with endometriosis, for which the drug 
is administered, that may influence the results of this study. Moreover, the effects 
of the drug itself may influence results. Accounting for these influences, however, 
would be ethically impossible to measure. For instance, the effects of GnRHaa 
therapy could be studied only by adding back the normal level of estrogen after 
decreasing its synthesis. The administration of GnRHaa with concurrent full add- 
back estrogen, however, is not medically justified. Albeit an animal study may 
have some merit.
Taking into consideration that group M represented the low estrogen status 
and group F represented the high estrogen status during the menstrual cycle, it 
was surprising that group M did not demonstrate any significant differences from 
group F. Astrup and associates (1992), found that plasma estradiol concentration 
explained only 4% and 6% of the variation of 24 hour carbohydrate oxidation and 
lipid oxidation, respectively, during the follicular phase. Perhaps this variation was 
too small to be detected as significant in this study. However, there is at least one 
reason why the differences were not as pronounced as they could have been and 
relate to a design problem that must be discussed. Group F comprised both low 
and high estrogen levels. The mean estrogen level of group F was significantly
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higher from the others, as expected, but the range overlapped considerably with 
group M. Even though no correlations were exhibited between estrogen, R, age 
and BMI in this study, a more defined picture of estrogen levels within the cycle 
could have been made by adding another group of late-follicular (pre-ovulatory) 
levels of estrogen to early follicular (menses) and mid-follicular levels (day 6-10). 
On the other hand, there is a question as to whether it is the absolute value of 
estrogen or the change in estrogen that is the important factor to consider. Also, 
some subjects may not have as wide a range of estrogen in their cycle. An 
alternate model that would eliminate within subject variability would be to test each 
subject at different phases of her menstrual cycle, and to test the GnRHaa group 
prior to beginning drug therapy and after two injections. However, this could not 
be done because of the possible confounding factor of pain that these subjects are 
experiencing prior to treatment
Other possible reasons that could have influenced results are related to 
problems that were encountered in testing. The resting data collection was 
compromised, due to the equipment not measuring variables @ very low VE’s, and 
this resulted in many missing values. Also, IV insertion may have caused variable 
responses, depending on how long it took to place the IV, and the subject’s pain 
threshold. A waiting period of at least five minutes after placement would be 
warranted.
Finding no statistical differences among groups in the above metabolic and 
cardiorespiratory studies are corroborated by the results of blood assays. 
Analyses of blood lactate, cortisol, ammonia and glucose revealed no differences
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among groups in their responses to increased workload from rest (0 minutes) to 
10 minutes of exercise, to 20 minutes of exercise at steady state. These results 
are partially supported by those of Bonen (1983), Kanaley (1992) and McCracken 
(1994) and their respective associates. Apparently, estrogen status does not 
affect these parameters at either rest or at low-to-moderate intensity, short 
duration exercise. These parameters changed with intensity as any normal 
population would. Also, the lack of intergroup differences is not surprising since 
these factors do not change appreciably during only 20 minutes of submaxima! 
intensity exercise. Twenty minutes is not enough time to notice a decrease in 
glucose (Pruett, 1971), or enough time or intensity to see depleted glycogen stores 
(Bergstrom, et a/., 1967). If there is no change in glucose utilization, indicating 
glycogen depletion, protein utilization, for the purpose of gluconeogenesis, would 
not be expected to increase (McArdle, et al., 1991). Therefore, ammonia, the 
byproduct of protein catabolism, would be unchanged. In addition, lactate 
concentrations do not change even after 90 minutes of submaximal exercise 
(Issekutz, et al., 1965). Finally, cortisol is released in response to high intensity 
or very prolonged exercise (Brooks, etal., 1996), neither of which differed among 
groups.
Blood lipids were not significantly different among groups even though other 
studies have found differences between pre- and postmenopausal females 
(Rainville & Vaccaro, 1984). It is possible that group G had not been 
hypoestrogenic for a long enough period of time. The average time that the 
subjects were hypoestrogenic was approximately four weeks. On the other hand,
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the study on the postmenopausal females, in the aforementioned study (Rainville 
& Vaccaro, 1984) had gone through natural menopause, and had not menstruated 
for at least a year prior to the experiment. Furthermore, studies of lipid 
metabolism have concluded that premenopausal cyclic changes in estrogen have 
only minor effects on lipid concentrations (Lebech, et al., 1990) and FFA 
mobilization (Heiling & Jensen, 1992).
Based on all non-significant results, it is no surprise that crossover points 
for the three groups were not significantly different. However, there was a 
tendency towards the crossover points of the low estrogen group M and G to be 
reached sooner (30.80 and 32.85 watts, respectively) than that of group F (34.79 
watts). This demonstrated that as intensity increased (and CHO utilization 
increased) the low estrogen groups came to 50% CHO more quickly than the 
highest estrogen group. These findings only corroborate, but cannot confirm, the 
present study’s hypothesis, i.e., that the pseudomenopausal estrogen status 
prefers carbohydrate to fat.
As in the resting analogy, the subtle metabolic differences found during 
exercise may have a long term effect on weight maintenance. For instance, if the 
results found at steady state were mainly attributed to estrogen status, as 
hypothesized, the tendency for carbohydrate utilization during moderate exercise 
might have a long term impact, just as seen in the previous resting analogy. 
Again, using the results of this study, of the fuel metabolized during steady state 
submaximal exercise, group F oxidized 63% carbohydrate and 37% fat (a 63:37 
ratio), as compared to 70% and 30%, respectively, for group G (a 70:30 ratio). For
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simplicity’s sake, assume that total caloric expenditure during each exercise 
session is 200 kcal, and that this is done 5 times per week totaling 1000 kcal per 
week (4000 kcal per month). Premenopausal energy expenditure during exercise 
using the 63:37 ratio would be 2520:1480 kcal or 630:164 grams (1 g CHO -  4 
kcal and 1 g fat = 9 kcal) per month. Postmenopausal values, using the 70:30 
ratio would be 2800:1200 kcal or 700:133.3 grams. This represents a decrease 
of 280 kcal or 31 grams of fat oxidized per month, and extending to a year, 3348 
kcal or 372 grams. Energy expenditure is the same, but there is a marked 
difference in the substrate oxidized. In other words, the calories expended are the 
same but they are not produced by the same substrate: a calorie is not a calorie. 
What are the long term consequences of this phenomenon? The preference of 
carbohydrate over fat should not affect body weight if all energy consumed is 
expended, but if the body is preferring to use CHO over fat, it is possible that 
protein/amino acid oxidation would occur (gluconeogenesis), and excess fat would 
be stored rather than used. It can be readily seen that the combined factors of 
CHO preference at rest and during submaximal exercise may result in weight gain. 
Under these circumstances, exercise may not counteract the weight gain that was 
shown to occur during resting metabolism. However, it certainly confirms the need 
and benefit to exercise regularly at a moderate level. These results are 
corroborated by a previous study performed by the author (Melton, ef a/., 1996) 
using the rat model. Ovariectomy resulted in weight gain, and was only partially 
ameliorated by swim training.
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Finally, trying to assess metabolic actions of a single hormone such as 
estrogen in an in vivo situation is a demanding task. Controlling for confounding 
factors is a major issue. In this study, there are at least two factors that could be 
limiting the present results. (1) Since body fat is positively correlated to estrogen 
levels, subjects with BMI’s of >25 could have been excluded from the study; (2) 
Groups comprised of women with a very wide age range. Two decades difference 
seen in this study may have an unknown influence, i.e., some subjects were twice 
as old as other subjects. Separating the age groups into 21-31 and 32-42, 
therefore, would define differences if they exist.
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CHAPTER 6. SUMMARY AND CONCLUSIONS
Clearly, estrogens have a major effect on the location and distribution of fat 
deposition in the body, as shown at puberty, when females begin to develop 
breasts, and to increase the size of the buttocks and thighs. After puberty, 
estrogens have an important role in fertility and maintaining the hormonal milieu 
during the childbearing years. At the end of the fertile cycle, the female 
experiences menopause, and estrogen levels decline to that of normal male 
values. During this time weight gain is a common occurrence (Wing, et al, 1991) 
and may be caused by a variety of factors. Since the weight gain is associated 
with chronically low estrogen status, there may be a link to the fuel mixture being 
used by the postmenopausal female, specifically, that of a higher ratio of 
carbohydrate to fat oxidation than what is used by premenopausal females. If 
carbohydrate is being utilized preferentially, the unused fat would be delivered to 
storage, thus increasing fat cell size and causing weight gain. Previous studies 
have demonstrated that estrogen status during phases of the menstrual cycle have 
been associated with fuel substrate utilization changes. The lack of estrogen, or 
low estrogen status, during the menopause has also been associated with lipid 
and glucose oxidation differences. The present study, used eumenhorreic 
subjects for comparison and GnRHaa-induced amenohorreic subjects as a 
postmenopausal model and determined fuel substrate utilization by indirect 
calorimetry. Whereas the results suggested possible differences due to estrogen 
status, these differences were not conclusive.
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Subjects in group M, with acutely low estrogen status (several days), did not 
generally respond in a similar fashion as the subjects in group G, who had 
chronically low estrogen status (a month or more). Keeping in mind that estrogen, 
as a steroid hormone, meets its receptor in the nucleus of the cell and activates 
the expression of genetic systems. This process takes a longer time to employ 
than those hormone-receptor systems that act immediately, e.g., insulin which 
meets its receptor on the target cell membrane activating glucose transport into 
the cell simultaneously. Subjects in group M, therefore, may not have had enough 
time to demonstrate the same results as those in group G, and may answer the 
question that Bunt (1990) raised: “...it is not known what is more relevant for acute 
exercise responses: chronic E2 status or E2 levels just prior to exerciseT.
Ambiguities still exist, however, and further research is necessary in order 
to more clearly define the trends that were demonstrated in this study. For 
example, one study that would eliminate the time factor difference between 
postmenopausal estrogen values mentioned above, using the GnRHaa model, test 
at one week after postmenopausal values have been established in order to mimic 
menses, and compare the results after 3 to 6 months of therapy.
Another ambiguity is the interaction of diet and estrogen status, and how 
these two affect fuel substrate utilization. A possible experiment may be set up to 
use the same three groups as this study, except limiting the follicular to pre­
ovulatory (highest estrogen status). The subjects would be placed on a controlled 
diet of high fat or high carbohydrate for a week. Using a metabolic chamber for 
a 24 hour period, the subjects could be tested for basal as well as exercise energy
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expenditure and carbohydrate and fat oxidation rates. If 24 hour urine were 
collected, protein utilization could also be established. It could be established that 
the postmenopausal female needs to increase her carbohydrate intake and reduce 
her fat intake in order to counter the body’s decrease in fat utilization and 
subsequent increase in fat storage.
Finally, the GnRHaa model could be used in an exercise training study. 
There are many ways to study training effects, but the caloric cost of training is an 
important aspect with respect to menopausal status. Is a calorie a calorie? In 
other words, is the postmenopausal female going to illicit the same benefits as a 
premenopausal female even if she is not using fat as readily? Investigating the 
long term effects of low estrogen status on fuel metabolism during a longitudinal 
training study would verify the calculations of the previous chapter.
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Table A. 1. Average R Values at Rest per Subject
Subject Group M Group F Group G
1 0.88± 0.05 0.79±0.05 0.88±0.04
2 0.87± 0.03 0.91 ±0.09 0.82±0.05
3 0.88± 0.05 0.77± 0.08 0.79±0.06
4 0.90± 0.15 0.93±0.10 0.85±0.10
5 0.94± 0.06 0.90 ±0.06 0.87±0.08
6 0.74± 0.04 0.85 ±0.02 1.03±0.13
7 0.94± 0.06 0.95± 0.08 0.97±0.09
8 0.89± 0.05 0.89±0.14
9 0.85± 0.04 0.81 ±0 .05
10 0.81 ±0.06 0.98± 0.11
11 0.96± 0.07 0.87± 0.07
12
13
14
Total Group 0.883± 0.06 0.891 ± 0.07 0.89 ±0.08
Values are mean ± standard deviation.
No significant differences among group means.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
74
Table A.2. Absolute and Relative Oxygen Consumption: V 0 2 (L/min) and 
V 0 2 (ml/kg/min) STPD of Subjects at Rest
Subject Group M 
L/min ml/kg/min
Group F 
L/min ml/kg/min
Group G 
L/min ml/kg/min
1 0.11±0.07 2.0±1.2 0.1410.05 2.410.9 0.0910.02 1.210.3
2 0.1410.02 2.310.4 0.1110.05 1.810.9 0.1210.04 1.810.8
3 0.2210.04 3.210.5 0.1810.13 2.112.0 0.1910.06 3.411.1
4 0.1010.02 1.710.4 0.1610.06 1.411.0 0.1110.02 1.710.5
5 0.1510.04 3.010.9 0.1710.11 2.812.1 0.1110.02 1.110.4
6 0.2110.05 3.310.8 0.0910.01 1.210.1 0.0710.01 1.410.3
7 0.1710.10 2.611.7 0.1310.02 2.210.4 0.1310.06 1.610.8
8 0.1710.11 2.511.9 0.1410.09 2.7H.8
9 0.1410.04 2.310.9 0.1210.04
2.110.8
10 0.1410.04 2.610.8 0.1210.02
2.410.4
11 0.1310.02 2.010.4 0.2310.08
2.311.7
12 0.1310.04
1.810.9
Group 0.1510.03 2.510.5 0.1410.03
2.110.4
0.1210.03 1.710.7'
Values are mean ± standard deviation. 
a Different from Group M (p = 0.0395)
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Table A.3. Carbon Dioxide Production (VC02in L/min) of Subjects at Rest.
Subject Group M Group F Group G
1 0.10±0.06 0.11±0.04 0.08±0.02
2 0.13±0.02 0.10±0.05 0.10±0.03
3 0.19±0.03 0.15±0.13 0.15±0.04
4 0.09±0.03 0.15±0.07 0.09±0.02
5 0.14±0.05 0.16±0.11 0.10±0.02
6 0.15±0.04 0.07±0.00 0.08±0.01
7 0.17±0.10 0.12±0.03 0.13±0.07
8 0.15±0.11 0.12±0.06
9 0.12±0.04 0.09±0.03
10 0.11 ±0.04 0.12±0.02
11 0.13±0.02 0.23±0.10
12 0.11 ±0.04
Group 0.14±0.02 0.13±0.04 0.10±0.02
Values are mean ± standard deviation.
No significant differences among group means.
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Table A.4. Average VE (BTPS) at Rest (Liters/minute).
Subject Group M Group F Group G
1 1.06±0.9 3.41 ±0.8 5.14±08
2 5.32±0.8 2.39±1.5 2.14±1.3
3 6.77±1.0 4.11 ±1.9 5.44±1.6
4 4.81±1.5 2.15±1.4 2.64±1.3
5 2.60±1.4 1.87±1.2 1.76±0.6
6 6.35±1.2 4.69±0.6 1.88±0.8
7 2.89±1.7 4.62±1.2 2.21±1.9
8 4.03±3.7 2.65±1.1
9 3.02±1.1 2.77±1.0
10 5.11±1.3 6.2±1.2
11 3.10±1.2 3.2±2.3
12 1.7±1.2
13
14
Group 4.10±1.7 3.33±1.36 3.07±1.5
Values are mean ± standard deviation.
No significant differences among group means.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
77
Table A.5. Average Heart Rate (HR) and Percent Age-predicted
Maximum Heart Rate (%HR) of Subjects at Rest.
Subject Group M 
HR(BPM) %HR
Group F 
HR (BPM) %HR
Group G 
HR (BPM) %HR
1 86.3±5.6 45.5±2.9 80.412.3
43.111.3
73.715.4 38.712.8
2 88.712.7 46.5±1.5 75.713.4
38.511.8
56.812.1 29.5H .1
3 66.813.3 35.311.7 83.415.5
42.912.9
69.912.5 35.8H.3
4 74.412.8 40.211.5 61.712.2
33.411.3
63.212.2 32.511.1
5 73.712.0 38.111.0 75.412.2
38.311.2
61.212.4 31.911.2
6 63.212.8 34.412.4 88.713.1
47.311.7
50.614.8 26.912.7
7 67.113.1 35.211.5
8 71.512.5 38.611.3
9 77.211.7 41.310.8
10 71.013.0 36.111.5
11
12
13
14
Group 74.018.2 39.114.2 76.0110.3
39.815.5 1
62.618.4 • 32.514.2 b
Values are mean ± standard deviation.
( Different from Group F (p = 0.0415) and Group M (p = 0.0549) 
b Different from Group F (p = 0.0344) and Group M (p = 0.0332)
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Table A.6. Percent Carbohydrate Used as a Fuel Substrate 
at Rest.
Subject Group M Group F Group G
1 61.9 31.4 63.5
2 42.6 71.3 58.8
3 31.2 25.6 61.2
4 54.3 79.6 68.7
5 69.5 68.3 81.5
6 100.0 52.4 14.1
7 92.2 88.2 81.0
8 63.1 65.9
9 34.5 52.8
10 100.0 40.1
11 95.2 89.4
12 59.1
13
14
GrouptSD 64.9±21.03 64.5±24.76 61.8±25.00
No significant differences among group means.
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Table A. 7. Kilocalories Expended Per Minute at Rest.
Subject Group M Group F Group G
1 0.62±1.06 0.72±0.45 0.23±0.42
2 0.96±0.19 0.33±0.48 0.73±0.45
3 0.42±0.50 0.80±0.83 1.03±0.19
4 0.88±0.33 0.77±0.66 0.66±0.48
5 1.03±0.19 0.88±0.32 0.14±0.36
6 1.0010.65 0.63±0.58 0.54±0.52
7 0.94±0.24 0.96±0.19
8 0.85±0.36 1.33±0.51
9 0.75±0.46
10
11
12
13
14
Group 0.78±0.17 0.72±0.19 0.61 ±0.17
Values are mean ± standard deviation.
No significant differences among group means.
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Table A.8. Kilocalories Expended per Liter Oxygen at Rest.
Subject Group M Group F Group G
1 4.75±0.10 4.77±0.07 4.8910.06
2 4.88±0.04 4.87±0.12 4.7610.09
3 4.90±0.06 4.70±0.05 4.7910.07
4 4.88±0.12 4.74±0.12 4.8010.12
5 4.86±0.14 4.76±0.12 4.7110.08
6 4.7310.04 4.77±0.09 4.8510.16
7 4.86±0.14 4.9610.08 4.8010.15
8 4.81±0.12 4.8410.12
9 4.79±0.09 4.7810.08
10 4.8210.08 5.0110.05
11 4.85±0.15 4.7510.12
12 4.7410.10
13
14
Group 4.90±0.08 4.9110.09 4.9110.09
Values are mean ±  standard deviation. 
No significant differences among group means.
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TABLE A.9. Resting Energy Expenditure (kcal/day).
Subject Group M Group F Group G
1 1181.38*1255.02 985.09*354.93 675.26*170.24
2 1072.93±194.59 756.66*323.64 857.93*294.51
3 764.15±182.85 1280.40*985.89 1312.59*407.91
4 1110.71*365.27 1306.67*865.78 785.00*202.94
5 1459.15*328.97 995.53*238.98 577.50*125.30
6 1209.53*849.31 1005.00*639.45 954.09*447.86
7 1104.35*362.62 927.92*178.63
8 1013.22*293.23 1671.00*596.13
g 996.50*326.13
10
11
12
13
14
Group 1122.00*247.68 1039.81*270.77 871.28*240.56
Values are mean 1 standard deviation.
No significant differences among group means.
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Table A. 10. Average R Values* of Subjects and Groups
at 0,10, 20, 30 and 40 Watts.
Subject Watts Group M Group F I Group G
1 0 0.8800 0.7054 0.7950
10 0.8700 0.7100 0.8200
20 0.9000 0.7700 0.8150
30 0.9250 0.8050 0.8450
40 1.0050 0.8050 0.8900
2 0 0.7300 0.7100 0.7050
10 0.8050 0.7800 0.7600
20 0.8350 0.7850
30 0.9200 0.8250 0.8050
40 0.9900 0.8500 0.8550
3 0 0.7450 0.7700
10 0.8150 0.7650
20 0.8400 0.8300 0.7450
30 0.9000 0.8650 0.8100
40 0.9750 0.9450 0.8450
4 0 0.7700 0.6800 0.7900
10 0.8000 0.7500 0.7450
20 0.8300 0.8150 0.8350
30 0.8350 0.8750 0.8650
40 0.8850 0.9650 0.8950
5 0 0.8500 0.7800 0.8050
10 0.8750 0.8000 0.8150
20 0.8900 0.8050 0.8150
30 0.9900 0.8200 0.8750
40 1.055 0.8900 0.8900
6 0 0.6950 0.7800 0.7700
10 0.7400 0.7800 0.8000
20 0.7600 0.7600 0.8500
30 0.7850 0.7900 0.8250
40 0.8550 0.8150 0.8850
7 0 0.7550 0.6800 0.8550
10 0.7900 0.8200 0.9000
20 0.8150 0.9100 0.8050
30 0.8200 0.9500 0.8050
40 0.8450 1.0400 0.8750
8 0 0.7100 0.6900
10 0.7900 0.7700
20 0.8150 0.7550
30 0.9000 0.7850
40 0.9450 0.8400
9 0 0.7150 0.7600
10 0.7850 0.8200
20 0.8000 0.8100
30 0.8100 0.7800
40 0.8050 0.8450
* Values are average of last two 30-second periods of each two minute stage. 
No Significant Differences among group means. 
(Table confd)
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Subject Watts GroupM Group F Group G
10 0 0.7900 0.7500
10 0.8300 0.7450
20 0.8350 0.8150
30 0.8500 0.9350
40 0.8650 0.9950
11 0 0.7600
10 0.8400
20 0.7950
30 0.9000
40 0.9850
12 0 0.7900
10 0.7750
20 0.7350
30 0.8100
40 0.8700
13 0 0.8700
10 0.8800
20 0.9000
30 0.9050
40 0.9300
14 0 0.8050
10 0.8700
20 0.8450
30 0.8900
40 0.9000
Group 0 0.7640 ±0.06 0.7525 ±0.06 0.7842 ±0.05
Means ± 10 0.8100 ±0.04 0.7969 ±0.05 0.7930 ±0.04
on 20 0.8320 ±0.04 0.8072 ±0.05 0.8071 ±0.03oU 30 0.8735 ±0.06 0.8488 ±0.05 0.8328 ±0.03
40 0.9225 ±0.08 0.9003 ±0.07 0.9225 ±0.03
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Table A. 11. Average Absolute (L) and Relative (ml/kg/min) Oxygen
Consumption Values* of Subjects at 0,10, 20, 30 and 40 Watts.
Subject Watts
Group M Gro IIP F GroijpG
L m l/kg/m in L ml/kg/min L m l/kg/m in
1 0 0.21 2.7 0.32 5.6 0.31 4.0
10 0.22 3.2 0.30 5.3 0.31 4.0
20 0.30 4.0 0.31 5.5 0.35 4.5
30 0.34 5.5 0.37 6.5 0.42 5.4
40 0.50 7.9 0.47 8.3 0.56 7.3
2 0 0.28 3.3 0.28 4.6 0.24 4.4
10 0.23 3.5 0.30 4.9 0.23 4.2
20 0.25 4.8 3 0.30 5.4
30 0.34 5.4 0.41 6.7 0.37 6.7
40 0.44 7.9 0.57 9.3 0.46 8.4
3 0 0.18 4.0 0.23 4.0
10 0.21 3.3 1.1 0.30 5.5
20 0.27 3.6 0.27 4.2 0.26 4.6
30 0.32 4.9 0.26 4.2 0.29 5.1
40 0.42 6.2 0.42 6.8 0.43 7.7
4 0 0.26 2.9 0.17 2.8 0.27 4.3
10 0.24 3.4 0.36 . 0.30 4.8
20 0.29 4.2 0.30 5.2 0.38 6.1
30 0.43 5.0 0.35 5.9 0.49 7.8
40 0.62 6.6 0.54 9 2 0.64 10.3
5 0 0.30 5.0 0.25 3.6 0.25 3.4
10 0.34 4.7 0.27 3.9 0.30 4.0
20 0.34 5.7 0.33 4.8 0.42 5.6
30 0.44 8.4 0.53 7.6 0.44 6.0
40 0.55 12.0 0.60 8.6 0.58 7.8
6 0 0.20 4.7 0.37 4.0 0.25 4.5
10 0.28 5.5 0.14 2.6 0.19 3.4
20 0.30 5.3 0.16 2.9 0.26 4.8
30 0.43 7.0 0.22 4.1 0.28 5.0
40 0.50 8.7 0.36 6.6 0.32 5.8
7 0 0.19 3.3 0.23 3.3 0.18 2.4
10 0.23 4.7 0.18 2.6 0.14 1.4
20 0.31 5.0 0.23 3.2 0.21 2.8
30 0.40 7.1 0.28 3.9 0.21 2.7
40 0.55 8.2 0.39 5.5 0.28 3.9
8 0 0.22 3.2 0.25 3.3
10 0.27 4.0 023 3.0
20 0.31 5.3 024 3.2
30 0.39 6.8 0.42 5.5
40 0.52 9.4 0.59 7.7
9 0 0.30 3.9 0.30 5.0
10 0.36 4.9 0.30 4.9
20 0.40 5.6 0.36 6.1
30 0.48 7.0 0.43 7 2
40 0.65 9.4 0.59 9.8
Values are average of last two 30-second periods of each two minute stage.
No Significant Differences among group means. 
(Table cont’d)*
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Subject Watts Group M Grotjp F GroiipG
L ml/kg/min L ml/kg/min L ml/kg/min
10 0 0.16 4.5 0.22 4.4
10 0.18 5.4 0.25 5.1
20 0.23 6.1 0.35 7.0
30 0.31 7.2 0.38 7.6
40 0.45 9.8 0.53 10.6
11 0 0.15 2.8
10 0.21 4.0
20 0.27 5.0
30 0.36 6.8
40 0.53 10.0
12 0 0.17 3.2
10 0.20 4.0
20 0.19 3.6
30 0.27 5.2
40 0.42 8.0
13 0 0.33 5.4
10 0.35 5.7
20 0.39 6.5
30 0.44 7.3
40 0.54 9.1
14 0 0.30 5.3
10 0.25 4.4
20 0.35 6.2
30 0.38 6.8
40 0.49 8.6
Group 0 0.2210.05 3.710.8 0.2510.06 4.111.3 02410.04 3.810.8
10 0.25±0.06 4.211.0 0.2610.06 7.7H7.6 02610.06 3.911.4Means z 20 0.30±0.05 4.910.9 0.2810.07 4.911.3 0.3110.07 4.811.1SD 30 0.3810.05 6.411.1 0.3610.08 6.111.3 0.3510.10 5.511.5
40 0.5110.07 8.611.6 0.5010.08 8.511.4 0.4610.13 7.311.9
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Table A. 12. Average Carbon Dioxide Production Values* (L/min) of Subjects
at 0,10,20, 30 and 40 Watts.
Subject W atts Group M Group F Group G
1 0 0.14 022 024
10 0.16 022 026
20 0.21 024 029
30 0.29 0.30 0.35
40 0.45 0.37 0.50
2 0 0.16 0.20 0.17
10 0.18 0.23 0.18
20 0.25 024
30 0.31 0.34 0.30
40 0.50 0.49 0.40
3 0 0.21 0.18
10 0.19 . 0.24
20 0.21 022 0.19
30 0.31 023 024
40 0.42 0.40 0.36
4 0 0.14 0.12 021
10 0.17 0.27 0.22
20 0.22 0.25 0.32
30 0.27 0.30 0.42
40 0.37 0.52 0.57
5 0 0.22 020 0.20
10 0.21 022 0.24
20 0.26 027 0.34
30 0.43 0.43 0.39
40 0.65 0.54 0.52
6 0 0.20 0.29 0.19
10 0.25 0.11 0.15
20 0.25 0.12 0.23
30 0.34 0.17 0.23
40 0.47 029 0.28
7 0 0.15 0.16 0.15
10 0.22 0.15 0.13
20 0.25 0.21 0.16
30 0.35 0.26 0.17
40 0.42 0.41 0.25
8 0 0.13 0.18
10 0.18 0.18
20 025 0.19
30 0.36 0.33
40 0.52 0.49
9 0 0.16 0.23
10 021 0.24
20 0.25 0.30
30 0.31 0.33
40 0.42 0.50
a Values are average of last two 30*second periods of each two minute stage. 
No Significant Differences among group means.
(Table confd)
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Subject Watts Group M Group F Group G
10 0 0.23 0.17
10 0.30 0.19
20 0.33 0.29
30 0.41 0.36
40 0.56 0.53
11 0 0.12
10 0.18
20 0.22
30 0.33
40 0.53
12 0 0.13
10 0.16
20 0.16
30 0.22
40 0.36
13 0 0.29
10 0.30
20 0.35
30 0.40
40 0.51
14 0 0.24
10 0.21
20 0.30
30 0.34
40 0.44
Group 0 0.17*0.04 0.19*0.05 0.19*0.03
Means ± 10 0.20*0.05 0.20*0.05 0.20*0.05
c n 20 0.24*0.04 0.23*0.06 0.25*0.06oU 30 0.33*0.05 0.31*0.07 0.29*0.09
40 0.47*0.08 0.45*0.08 0.40*0.12
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Table A. 13. Average Minute Ventilation (L/min) Values" of Subjects and
Groups at 0,10,20, 30 and 40 Watts.
Subject Watts Group M Group F Group G
1 0 4.1 5.3 10.0
10 4.9 6.7 10.5
20 5.9 8.8 11.1
30 8.8 10.7 125
40 13.6 13.1 16.9
2 0 5.3 5.3 3.1
10 6.0 7.7 3.5
20 7.5 6.2
30 9.6 10.6 8.1
40 15.8 13.9 11.1
3 0 3.4 0.4 4.1
10 4.9 2.5 4.5
20 6.3 3.6 6.1
30 9.1 6.7 7.7
40 13.3 12.8 11.1
4 0 5.3 5.4 7.9
10 6.7 7.8 6.5
20 9.3 9.8 9.9
30 11.4 12.7 13.4
40 14.7 17.2 16.6
5 0 8.1 6.1 5.2
10 8.4 7.1 7.2
20 10.4 8.5 9.1
30 16.0 123 10.3
40 22.8 15.3 13.6
6 0 7.8 20 3.1
10 9.2 1.6 2 3
20 9.9 3.0 5.1
30 13.2 5.2 6.6
40 17.3 8.3 8.8
7 0 4.2 4.0 2 5
10 5.4 7.0 3.0
20 8.0 9.0 2 6
30 11.1 1.0 4.1
40 12.2 15.0 6.6
8 0 3.8 3.5
10 6.1 4.7
20 8.2 5.1
30 11.2 11.3
40 15.2 15.9
g 0 5.4 7.8
10 7.3 8.7
20 9.2 11.3
30 11.1 11.8
40 13.2 16.6
Values are average of last two 30-second periods of each two minute stage 
"Different from Group M (p=0.0684) 
(Table cont’d)
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Subject Watts Group M Group F Group G
10 0
10
20
30
40
8.3
9.8
11.1
13.4
17.5
5.3 
5.7
7.4 
10.5 
1£5
11 0 2.6
10 5.1
20 5.7
30 10.1
40 14.8
12 0 4.6
10 4.7
20 4.2
30 6.6
40 10.3
13 0 72
10 7.8
20 8.7
30 9.5
40 11.8
14 0 5.9
10 6.1
20 8.0
30 10.1
40 13.2
Group 
Means ± 
SD
0
10
20
30
40
5.58±1.84
5.91±2.23
8.59t1.78
11.50t2.25
15.56±3.23
4.71±2.11
6.89±1.79
7.09±2.66
9.91t2.43
13.60t2.92
5.13t2.77
5.37t2.89
7.14i2.92
9.00±3.24
12.12t3.75“
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Table A. 14. Average HR and Percent Age-predicted HR maximum (%HR) 
Values* of Subjects at 0 ,1 0 ,2 0 ,3 0  and 40 Watts.
Subject Watts Group M GroupF GroiipG
HR %HR HR %HR HR %HR
t 0 107 57 85 46 101 52
10 112 59 88 47 102 53
20 114 60 89 48 109 56
30 121 64 99 53 120 62
40 138 73 107 58 123 64
2 0 98 51 92 50 83 44
10 103 54 96 53 83 44
20 107 56 98 91 48
30 114 60 103 56 87 51
40 124 66 114 62 106 56
3 0 86 46 90 48 71 37
10 91 48 95 51 74 39
20 95 50 97 52 80 42
30 106 56 104 56 86 44
40 113 60 • 97 50
4 0 79 43 88 45
10 100 52 94 51 93 48
20 104 54 99 54 101 52
30 115 60 109 59 108 56
40 126 66 120 65 117 61
5 0 90 49 103 53 82 42
10 93 50 110 56 86 44
20 95 52 118 60 94 48
30 106 58 126 65 98 50
40 118 64 142 73 104 54
6 0 86 44 83 45 88 46
10 90 47 86 47 90 47
20 86 49 90 49 94 49
30 106 54 105 57 105 55
40 112 58 112 61 117 62
7 0 81 44 87 48 78 42
10 86 46 89 49 81 43
20 91 49 98 54 85 45
30 97 52 108 60 90 48
40 107 58 123 68 99 53
8 0 90 47 87 44
10 95 50 92 47
20 103 54 105 54
30 115 60 119 61
40 133 70 135 69
* Values are average of last two 30-second periods of each two minute stage 
“Different from Group F (p = 0.0525) 
(Table cont’d)
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Subject Watts GroiJP M GroijpF GroupG
HR %HR HR %HR HR %HR
g 0 84 46 101 52
10 87 47 107 55
20 90 49 108 55
30 98 53 114 58
40 105 57 126 64
10 0 84 43 94 49
10 90 46 99 51
20 93 48 106 54
30 98 50 116 60
40 109 56 126 65
11 0 79 43
10 81 44
20 86 46
30 94 51
40 107 58
12 0 89 45
10 93 47
20 99 51
30 107 54
40 114 59
13 0 85 44
10 88 45
20 86 44
30 92 47
40 99 50
14 0 104 56
10 107 57
20 112 60
30 118 63
40 125 67
Group 0 89.3 ±8.0 47.2 ±4.2 90.2 ±8.5 47.6 ±4.1 82.9 ±6.4 43.2 ±4.2
Means ± 10 94.6 ±9.3 49.8 ±4.4 94.6 ±9.3 49.8 ±4.4 85.7 ±8.0 44.6 ±4.0 •20 98.2 ±8.0 51.8 ±4.0 98.5 ±10.3 51.6 ±5.0 91.9 ±8.5 47.8 ±4.1SD 30 106.8 ±8.2 56.2 ±4.2 106.5±9.7 56.1 ±5.0 98.6 ±10.1 51.3 ±5.1
40 117.8 62.0 ±6.0 116.5 ±11.2 61.3 ±5.8 107.6 ±9.3 56.2 ±4.8
±11.3
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Table A. 15. Average Percent Carbohydrate Values* of Subjects
at 0,10, 20, 30 and 40 Watts.
Subject Watts GroupM Group F Group G
1 0 60.81 4.20 31.61
10 57.45 X38 40.33
20 67.51 2X74 38.58
30 75.78 35.06 48.93
40 100.00 35.11 64.10
2 0 8.39 6.01 4X0
10 35.09 26.31 19.17
20 45.51 0 28.09
30 74.01 41.96 35.11
40 96.81 50.65 5X36
3 0 13.71 0 2X69
10 36.54 0 20.99
20 47.22 43.79 13.82
30 67.51 55.76 36.85
40 92.01 8X31 48.94
4 0 23.61 0 29.85
10 33.36 7.81 13.80
20 43.71 38.42 45.46
30 45.51 59.12 55.65
40 62.48 88.76 65.74
5 0 50.65 26.32 35.09
10 59.14 33.28 38.58
20 64.17 35.11 38.58
30 95.21 40.25 59.14
40 100.00 64.17 64.04
6 0 0 13.16 2X44
10 1X 01 13.16 33.36
20 19.20 19.13 50.62
30 28.07 29.85 41.96
40 5X36 38.56 6X50
7 0 17.36 0 5X19
10 29.77 20.16 33.75
20 38.60 35.41 35.00
30 40.33 41.97 35.09
40 48.89 50.00 59.14
8 0 X38 0
10 29.84 2X69
20 38.58 17.40
30 67.51 27.98
40 8X33 47.23
9 0 X93 19.17
10 28.09 40.25
20 33.36 36.72
30 36.85 26.31
40 35.01 48.94
Values are average of last two 30-second periods of each two minute stage. 
No Significant Differences among group means. 
(Table confd)
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Subject W atts Group M Group F Group G
10 0 29.85 18.43
10 43.79 13.80
20 45.51 38.60
30 50.66 79.01
40 55.70 88.71
11 0 19.20
10 47.22
20 31.61
30 67.51
40 95.21
12 0 29.84
10 24.49
20 10.19
30 36.85
40 57.42
13 0 57.31
10 60.61
20 67.51
30 69.07
40 77.39
14 0 34.74
10 57.44
20 48.93
30 64.17
40 67.51
Group 0 20.97 ±22.3 16.31 ±19.2 28.30 ±18.1
10 36.71 ±14.6 26.42 ±21.0 28.57 ±17.1M 6011S z 20 44.34 ±14.3 31.82 ±20.6 35.74 ±13.6so 30 58.14 ±21.1 48.21 ±21.7 44.68 ±1Z1
40 7Z56 ±24.4 63.71 ±24.3 59.55 ±10.23
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Table A. 16. Average* Kilocalories Expended Per Liter of Oxygen
of Subjects at 0,10, 20, 30 and 40 Watts.
Subject Watts Group M Group F GroupG
1 0 4.B9 4.70 4.79
10 4.88 4.69 4.82
20 4.92 4.76 4.81
30 4.95 4.80 4.85
40 5.04 4.80 4.91
2 0 4.71 4.70 4.70
10 4.80 4.77 4.75
20 4.84 4.68 4.78
30 4.94 4.83 4.80
40 5.03 4.86 4.86
3 0 4.73 4.68 4.76
10 4.81 4.68 4.75
20 4.84 4.83 4.73
30 4.92 4.88 4.81
40 5.01 4.97 4.85
4 0 4.76 4.68 4.78
10 4.80 4.71 4.73
20 4.83 4.81 4.84
30 4.84 4.89 4.88
40 4.90 5.00 4.91
5 0 4.86 4.77 4.80
10 4.89 4.80 4.81
20 4.91 4.80 4.81
30 5.02 4.82 4.89
40 5.04 4.91 4.91
6 0 4.68 4.73 4.76
10 4.72 4.73 4.80
20 4.75 4.75 4.86
30 4.78 4.78 4.83
40 4.86 4.81 4.90
7 0 4.74 4.68 4.86
10 4.78 4.75 4.80
20 4.81 4.81 4.80
30 4.82 4.83 4.60
40 4.85 4.86 4.89
8 0 4.69 4.68
10 4.78 4.76
20 4.81 4.74
30 4.92 4.78
40 4.97 4.84
9 0 4.69 4.7510 4.78 4.82
20 4.80 4.81
30 4.81 4.77
40 4.80 4.85
Values are average of last two 30-second periods of each two minute stage. 
No Significant Differences among group means. 
(Table confd)
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Subject Watts Group M Group F Group G
10 0 4.78 4.74
10 4.83 4.73
20 4.84 4.81
30 4.86 4.96
40 4.88 5.00
11 0 4.75
10 4.84
20 4.79
30 4.92
40 5.02
12 0 4.78
10 4.76
20 4.72
30 4.81
40 4.88
13 0 4.88
10 4.89
20 4.92
30 4.92
40 4.96
14 0 4.80
10 4.88
20 4.85
30 4.91
40 4.92
Group 0 4.75±0.07 4.7410.06 4.78*0.06
M oans + 10 4.81±0.05 4.7710.07 4.7810.06
20 4.84±0.05 4.7910.07 4.8010.04
SO 30 4.89±0.07 4.8510.07 4.8410.04
40 4.9410.09 4.9110.08 4.8910.03
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Table A. 17. Average* Kilocalories Expended Per Minute
at 0,10, 20, 30 and 40 Watts.
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Subject Watts Group M Group F Group G
1 0 1.0 1.0 1.5
10 1.0 1.5 1.5
20 1.0 1.5 ZO
30 1.5 ZO ZO
40 Z0 ZO 3.0
2 0 1.0 1.0 1.0
10 1.0 1.5 1.0
20 1.5 1.5
30 ZO ZO ZO
40 Z 5 3.0 ZO
3 0 1.5 1.0
10 1.0 1.5
20 1.0 1.0 1.0
30 ZO 1.0 1.0
40 ZO ZO ZO
4 0 1.0 1.0 1.0
10 1.0 ZO 1.5
20 1.0 1.5 ZO
30 1.5 ZO ZO
40 ZO Z5 3.0
5 0 1.0 1.0 1.0
10 1.0 1.0 1.5
20 1.5 ZO ZO
30 ZO 3.0 ZO
40 3.0 3.0 3.0
6 0 1.0 ZO 1.0
10 1.5 1.0 1.0
20 ZO 1.0 1.0
30 ZO 1.0 1.0
40 3.0 ZO ZO
7 0 1.0 1.0
10 1.0 1.0
20 1.5 1.0
30 ZO 1.0
40 ZO 1.0
8 0 1.0 1.0
10 1.0 1.0
20 1.5 1.0
30 ZO ZO
40 3.0 3.0
9 0 1.0
10 1.0 .
20 1.5 .
30 ZO .
40 Z 5
* Values are average of last two 30-second periods of each two minute stage 
No significant differences among group means 
(Table cont’d)
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Subject Watts Group M Group F Group G
10 0 1.0 1.0
10 2.0 1.0
20 2.0 1.5
30 2.0 2.0
40 3.0 3.0
11 0
10
20 .
30
40
12 0 1.0
10 1.0
20 1.0
30 1.0
40 2.0
13 0 1.5
10 2.0
20 2.0
30 2.0
40 3.0
14 0 1.5
10 1.0
20 2.0
30 2.0
40 2.5
Group 0 1.05 ±0.22 1.15*0.37 1.07*0.26
Means ± 10 1.15 ±0.36 1.27*0.46 1.30*0.48
20 1.45*0.51 1.45*0.51 1.50 ±0.51o U 30 1.90*0.30 1.61 *0.58 1.57*0.51
40 2.5*0.51 2.54 *0.50 2.28 ±0.72
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Table A.18. Average R Values of Last 5 Minutes of Exercise
(60% Age-predicted Maximum Heart Rate).
Subject Group M Group F Group G
1 0.86 ±0.01 0.90 ± 0.04 0.89 ± 0.04
2 0.87 ±0.01 0.89 ±  0.02 0.94 ±  0.01
3 0.92 ± 0.02 0.88 ±  0.02 0.89 ± 0.04
4 0.90 ± 0.02 0.93 ±  0.01 0.92 ± 0.03
5 0.96 ±0 .02 0.95 ±  0.04 0.90 ±  0.03
6 0.83 ±0.01 0.86 ±  0.02 0.90 ± 0.02
7 0.89 ± 0.02 0.80 ±  0.02 0.88 ± 0.01
8 0.87 ± 0.01 1.02 ± 0.03
9 0.82 ± 0.02 0.88 ±  0.04
10 0.94 ± 0.03 0.85 ± 0.01
11 0.87 ± 0.01
12 0.83 ± 0.01
13 0.86 ± 0.03
14 0.87 ± 0.02
Group
.
0.891 ±0.04 0.888 ±0.06 0.908 ± 0.03
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table A. 19. Average Absolute and Relative Oxygen Consumption: V 02 (L) and 
V 0 2 (ml/kg/min) STPD during the Last 5 minutes of Exercise 
(60% Age-predicted Maximum Heart Rate).
Subject I Group M Group F GroupG
<L> ml/kg/min (L) m l/kgm in (L) ml/kgmin
1 0.2210.02 3.9710.38 0.5310.53 9.5110.59 0.4510.07 5.9410.99
2 0.2910.06 4.7011.04 0.4510.07 7.4811.16 0.4810.04 8.8910.79
3 0.3810.04 5.5810.60 0.2710.01 4.4110.23 0.5510.05 9.9110.89
4 0.2910.02 4.5910.39 0.3310.03 5.7210.66 0.5310.04 8.6010.76
5 0.4610.01 9.0510.38 0.2510.03 3.7710.45 0.8210.10 11.1511.49
6 0.5710.04 9.2410.73 0.4110.05 7.6511.02 0.4110.03 7.5810.64
7 0.70* 0.04 11.6710.71 0.2410.10 3.4611.49 0.3410.03 4.6610.51
8 0.2910.03 5.0710.51 0.3110.09 4.1511.21
9 0.5710.03 10.3210.57 0.5010.04 8.3310.65
10 0.8110.07 12.2711.14 0.4410.05 8.9311.18
11 0.4910.02 9.3310.52
12 0.4710.05 9.1510.95
13 0.9710.05 16.1110.94
14 0.2910.04 5.2010.69
Group 0.4610.19 7.6413.11 0.4310.18 7.5213.32 0.5110.15 8.101227
Values are mean ± standard deviation. 
No Significant Differences among group means.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
100
Table A.20. Average Carbon Dioxide (VC02 in L/min) STPD Production in the
Last 5 Minutes of Exercise (60% Age-predicted Maximum Heart
Rate).
Subject Group M Group F Group G
1 0.19±0.02 0.45±0.03 0.40±0.07
2 0.26±0.05 0.40±0.05 0.43±0.04
3 0.36±0.04 0.24±0.01 0.50±0.05
4 0.26±0.02 0.28±0.02 0.48±0.05
5 0.44±0.02 0.22±0.03 0.76±0.10
6 0.48±0.03 0.35±0.05 0.37±0.04
7 0.63±0.04 0.21 ±0.08 0.32±0.04
8 0.25±0.02 0.25±0.08
9 0.47±0.02 0.43±0.04
10 0.76±0.08 0.42±0.05
11 0.46±0.02
12 0.42±0.04
13 0.99±0.08
14 0.26±0.03
Group 0.41 ±0.17 0.39±0.19 0.46±0.14
Values are means ± SD.
No Significant Differences among group means.
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Table A.21. Average VE (6TPS) during the Last 5 minutes of Exercise
(60% Age-predicted Maximum Heart Rate).
Subject Group M Group F Group G
1 5.57±0.73 15.7011.03 14.1812.59
2 8.18±1.67 13.8511.26 12.3811.10
3 11.71*1.18 7.7410.67 16.6411.15
4 12.16±1.08 11.9810.83 15.0611.87
5 17.9311.03 6.84H .12 20.8212.16
6 17.2611.16 10.9111.48 12.2511.78
7 18.2911.22 10.0010.70 9.3111.03
8 8.9310.85 8.0913.09
9 15.3210.70 14.9311.62
10 22.8912.31 12.12l2.13
11 15.6710.87
12 12.7211.62
13 23.54l2.73
14 7.8711.15
Group 13.8215.30 12.3414.59 14.3713.82
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table A.22. Average Percent Carbohydrate Used as a Fuel Substrate
During the Last 5 minutes of Exercise (60% Age-predicted
Maximum Heart Rate).
Subject Group M Group F Group G
1 55.41 ±3.97 51.32±5.29 64.69±15.04
2 59.11 ±6.39 61.32±16.02 63.49± 4.69
3 76.08±7.10 60.46±5.58 68.81± 7.01
4 68.47±7.66 40.43±14.84 68.40±13.00
5 88.77±7.14 53.94±13.15 75.70±11.02
6 44.81 ±4.61 58.09±7.55 67.05±14.04
7 67.15±7.08 34.03±37.01 82.63± 5.97
8 58.44±5.74 34.01 ±8.83
9 43.41 ±7.39 54.68±9.58
10 82.26±9.96 84.19±11.47
11 80.04±3.71
12 62.45±8.43
13 98.07±5.06
14 67.13±8.81
Group 64.39±15.79 63.20±16.82 70.11±12.12
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table A.23. Average Kilocalories Expended Per Liter of Oxygen Consumed
During the Last 5 minutes of Exercise (60% Age-predicted
Maximum Heart Rate).
Subject Group M Group F Group M
1 4.87±0.01 4.8610.01 4.9110.05
2 4.89±0.02 4.9010.05 4.9010.01
3 4.95±0.02 4.8910.02 4.9210.02
4 4.92±0.02 4.8210.05 4.9210.04
5 5.00±0.02 4.8710.04 4.9510.04
6 4.8410.01 4.8810.02 4.9210.05
7 4.9210.02 4.8010.13 4.9810.02
8 4.8910.02 4.8010.03
9 4.8310.02 4.8710.03
10 4.9710.03 4.9810.04
11 4.9710.01
12 4.9010.03
13 5.0310.01
14 4.9210.03
Group 4.9110.05 4.9110.06 4.9310.04
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table A.24. Average Kilocalories Expended Per Minute During the Last 5
Minutes of Exercise (60% Age-predicted Maximum Heart Rate).
Subject Group M Group F Group G
1 1.00 ±0.00 2.70 ±0.48 2.40 ±0.69
2 1.50 ±0.52 2.20 ±0.42 2.30 ±0.48
3 2.00 ±0.00 1.00 ±0.00 2.80 ±0.42
4 1.20 ±0.42 1.77 ±0.44 2.70 ±0.48
5 2.00 ±0.00 1.10 ±0.31 4.30 ±0.67
6 3.00 ±0.00 2.10 ±0.31 2.00 ±0.00
7 3.60 ±0.51 1.40 ±0.51 1.80 ±0.42
8 1.50 ±0.52 2.1 ±0.31
9 3.00 ±0.00 2.3 ±0.48
10 4.00 ±0.47 4.9 ±0.31
11 1.4 ±0.51
12
13
14
Group 2.28 ±1 .05 2.11± 0.94 2.55 ± 0.76
Values are mean ± standard deviation.
No Significant Differences among group means.
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Table A.25. Average Work (KPMs) during the Last 5 Minutes of Exercise
(60% Age-predicted Maximum Heart Rate).
Subject Group M Group F Group G
1 71.0 ±15.99 271.5 ±8.2 126.9 ±4.84
2 109.3 ±5.49 205.6 ±33.43 236.4 ±24.84
3 206.9 ±7.03 154.0 ±0.00 267.0 ±12.38
4 149.2 ±3.48 143.2 ±13.84 210.9 ±10.53
5 169.4 ±10.46 100.0 ±12.20 282.1 ±16.98
6 229.3 ±12.05 252.7 ±7.46 247.0 ±0.00
7 298.9 ±6.29 151.1 ±39.14 256.1 ±23.64
8 108.8 ±13.79 189.9 ±9.9
9 277.0 ±0.00 255.4 ±14.13
10 290.0 ±31.96 369.0 ±0.00
11 92.0 ±9.60
12
13
14
Group 190.98±79.31 190.40±94.47 232.34±50.54
Values are mean ± standard deviation.
No Significant Differences among means.
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Table A.26. Average Work (Watts) during the Last 5 minutes of Exercise
(60% Age-predicted Maximum Heart Rate).
Subject Group M Group F Group G
1 11.80 44.30 20.50
2 18.10 33.60 38.50
3 33.70 25.00 43.50
4 24.60 23.50 34.30
5 27.60 1.80 46.30
6 37.50 41.30 40.00
7 48.90 13.80 41.90
8 17.80 24.80
9 45.00 34.00
10 47.40 31.10
11 32.80
12 41.80
13 60.00
14 15.40
Overall Group 
Average ± SD
31.24 ±12.87 30.83± 14.27 37.85± 8.36
Values are mean ± standard deviation.
No Significant Differences among means.
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Table B.1. Serum Estrogen Levels of Subjects at Rest (pg/ml).
Subject Group M Group F Group G
1 38.20 39.61 6.28
2 43.46 44.30 3.56
3 41.39 99.23 3.20
4 92.43 425.98 <1.00
5 50.10 91.36 3.75
6 97.70 60.92 20.71
7 69.08 553.31 12.67
8 12.25 83.67
9 80.92 149.07
10 38.83 117.18
11 58.47
12 782.77
13 80.26
14 456.27
Group 56.43±
27.4*
217.31 ± 
236.25
7.31± 
6.98 b
Values are mean ± standard deviation. 
a Different from Group F (p < .05). 
b Different from Group F (p < .01).
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Table B.2. Fasting Lipids of Subjects (mg/dl).
109
s
u
B
J
E
C
T
CH
M
TOTAL
OLESTEI
Group
F
ROL
G
CHO
M
HDL
LESTEI
Group
F
ROL
G
CH
M
LDL
OLESTEROL
Group 
F G
TRK
M
3LYCERIDES
Group
F G
1 128 115 167 54 49 55 65.6 51.2 90.2 42 74 109
2 177 210 161 30 61 66 90 135.4 82.6 285 68 62
3 152 195 207 33 69 57 101.4 111 133.8 88 75 81
4 164 146 166 53 56 51 96.2 77.8 101.6 74 61 67
5 164 154 161 46 50 42 100.4 91.4 108.6 88 63 52
6 149 165 102 49 70 50 91.4 106.6 47 43 47 25
7 155 209 50 58 89.2 130.4 79 103
8 166 151 78 52 78.6 89 47 50
9 180 169 46 56 112.2 102.6 109 52
1
0
150 175 44 58 93 102 65 75
1
1
167 63 96.8 36
1
2
163 53 100.4 47
1
3
195 54 117.8 116
1
4
138 42 77.4 93
G
R
0
U
P
158.5
t15.1
169.4
*27 .6
160.6
*33 .6
48.3
*13 .0
56.5
*7 .6
53.5
*8.0
91.8
*12.7
99 2
*21.9
93.9
*29.0
92
*7 1 2
68.5
*22.9
66
*28.1
No significant differences among groups.
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Table B.3. Hematocrit at Rest (0), at 10 and 20 Minutes during Exercise.
Subject Time Group M Group F Group G
1 0 41 37 37
10 39 40 38
20 40 37
2 0 38 37 43
10 39 37 42
20 38 36 43
3 0 38 40 43
10 40 40 43
20 40 35 40
4 0 39 39 38
10 39 40 36
20 37 40 38
5 0 39 36 40
10 39 38 41
20 40 36 42
6 0 38 40 39
10 38 43 43
20 36 34 45
7 0 36 3
10 37 41
20 37 40
8 0 37 38
10 39 38
20 41 38
9 0 41 36
10 41 37
20 39
10 0 40 35
10 40 36
20 40 -
11 0 39
10
20 42
12 0
10
20
13 0
10
20
14 0
10
20
Group 0 38.7±1.6 37.6*1.6 40.0*2.5 *
MeanstSD 10 39.1*1.1 39.0*2.1 40.8*2.3
20 38.8±1.6 37.6*2.8 40.8*3.0 1
Values are percent whole blood * Different from Group F ©  0 (p<0.05) '  Different from Group F ©  20 (p<0.05)
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Table B.4. Plasma Glucose at Rest (0), at 10 and 20 Minutes during Exercise.
Subiect Time Group M Group F Group G
1 0 82 88 109
10 78 74 108
20 75 49 108
2 0 84 88 82
10 91 88 93
20 88 85 90
3 0 92 84 85
10 96 92 84
20 95 108 87
4 0 92 96
10 89 75 95
20 94 75 93
5 0 82 80 83
10 86 75 86
20 77 79 82
6 0 85 83 86
10 85 78 85
20 83 77 83
7 0 92 89
10 91 93
20 88 92
8 0 89 75
10 83 82
20 84 81
9 0 89 97
10 79 101
20 77 101
10 0 81 89
10 84 86
20 - 76
11 0 84
10 84
20 77 79
12 0 80
10 83
20 -
13 0 90
10 91
20 86
14 0 40
10 87
20 83
Group 0 86.8*4.4 82.4*12.5 90.1*10.4
Means 10 86.015.3 85.0*8.1 91.8*9.1
±SD 20 83.8*7.3 82.3*14.0 90.5*9.5
Values are mg/dl. No Significant Differences within or among group means.
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Table B.5. Plasma NH3 at Rest (0), at 10 and 20 Minutes during Exercise.
Subject Time 0 Minutes 10 Minutes 20 Minutes
1 0 14 24 20
10 16 15 26
20 18 8 28
2 0 14 17 36
10 21 23 33
20 19 27 32
3 0 27 60 22
10 19 80 27
20 25 130 38
4 0 18 15
10 21 37 25
20 28 37 25
5 0 27 26 28
10 18 24 53
20 35 23 54
6 0 15 21 27
10 24 17 32
20 25 19 30
7 0 16 25
10 20 30
20 26 62
8 0 16 32
10 25 26
20 22 39
9 0 11 15
10 16 18
20 22 18
10 0 28 19
10 28 21
20 • 24
11 0 19
10 34 .
20 35 39
12 0 31
10 25
20
13 0 26
10 22
20 22
14 0 13
10 33
20 25
Group 0 18.6*6.2* 25.2*11.9 24.6*7.3
Means ± 10 22±5.4 28.5*16.6 32.6*10.4
SD 20 25.5*5.8 36.3*31.1 34.5*10.5
Values are pmol/L No Significant Differences among group means. * Different from 20 (p < .05).
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Table B.6. Plasma Lactate at Rest (0), at 10 and 20 Minutes during Exercise.
Time Group MSubject Group F Group G
0.6
1.3
1.3
1.0
0.8
0.5
1.4
2.2
1.5
1.3
3.4 
2.8
0.7
2.6
3.0
2.1
1.8
1.2
1.6
2.1
1.0
1.6
20
0.8 
12. 
1.0
0.7
20
2223
1.5
3.6 
5.0
1.0
20
20
1.1
1.3
1.0
0.6
0.9
0.7
0.7 1.1
1.7
221.2
1.3 
1.2
1.4
1.8
3.6
24
1.5 
23
1.6
20
1.3
1.0 1.3
1.8
1.71.0
1.3
3.4
1.3 
27
3.4
1.5
1.3 4.6
1.2
1.8
1.2
1.5
1.9
0.7
3.0
29
1.1*0.3 
1.9*1.0 
1.8* 1.2
1.1*0.3' 
1.9*0.8 
22* 1.1
1.0* 0.2** 
1.9*0.2 
1.9*0.2
Group
Means*SD
Values are mmol/L.
•Different from 10 (p<0.01) and 20 (p<0.05). —Different from 10 and 20 (p < 0.01).
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Table B.7. Serum Cortisol at Rest (0), at 10 and 20 Minutes during Exercise.
Subject Time GrouoM Group F Group G
1 0 7.96 14.79 1233
10 7.11 13.84 11.95
20 6.40 • 13.85
2 0 11.92 13.51 16.50
10 13.52 1260 14.74
20 11.97 1259 14.20
3 0 6.08 1294 18.97
10 5.87 11.59 21.35
20 4.58 10.35 20.40
4 0 17.14 24.77 14.14
10 15.16 2279 11.39
20 1255 20.09 11.09
5 0 12.22 27.70 1281
10 10.74 23.80 11.95
20 11.52 2272 10.34
6 0 14.23 11.88 11.31
10 1262 16.05 11.35
20 9.16 11.65 10.51
7 0 20.82 4.64
10 20.53 8.11
20 17.98
8 0 20.08 10.94
10 16.21 18.71
20 13.68 20.97
9 0 15.60 24.50
10 20.23 27.29
20 19.78 19.22
10 0 15.24 18.21
10 13.78 20.49
20 13.32 16.70
11 0 9.56
10 7.81
20 9.71
12 0 16.02
10 14.03
20 1278
13 0 24.66
10 21.58
20 21.16
14 0 21.42
10 20.61
20 19.05
Group 0 14.1314.76 16.8216.88 14.341288
MeantSO 10 13.5814.85 17.0915.99 13.7813.91
20 120914.66 16.4214.71 13.4013.81
Values are pg/dl. No Significant Differences among group means.
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Table C. 1. 24 Hour Dietary Analysis
116
s Group M GroupF Group G
b
i
e
c
t
Total
kcal
CHO
%
Fat
%
Pro
% Total
kcal
CHO
%
Fat
%
Pro
% Total
kcal
CHO
%
Fat
%
Pro
%
1 2052 38 18 43 1785 19 15 66 1733 25 19 56
2 1218 28 23 49 1076 24 16 60 2060 24 13 63
3 1406 18 15 66 1453 26 25 49 1713 18 19 63
4 1879 28 16 55 1809 22 19 58 1934 29 18 53
5 3195 28 23 48 2574 27 27 46 2352 44 19 37
6 896 44 19 36 1377 35 19 45 1109 35 15 49
7 2200 41 9 50 2107 24 20 56 3018 11 11 78
8 1976 28 12 60 820 29 12 59
9 2429 31 26 43 2439 37 16 47
10 3052 31 15 53 3643 18 11 71
11 1683 23 32 45
12 1411 35 19 46
13 1883 24 18 57
14 3455 33 18 49
Mean
±SD
2030.3
±741.6
31.5
±7.6
17.6
±5.2
50.3
±8.7
1979.6
±655.6
26.8
±6.0
19.0
±5.6
53.8
±8.3
1988.4
±593.6
26.5
±10.8
16.2
±3.3
57.0
±12.8
No Significant Differences among group means.
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COLLABORATIVE STUDY OF LSU DEPARTMENT OF KINESIOLOGY AND 
WOMAN’S HEALTH RESEARCH INSTITUTE: 
THE EFFECTS OF HYPOESTROGENISM ON RESTING AND ACUTE 
SUBMAXIMAL EXERCISE METABOLISM USING THE GNRHaa MODEL 
INFORMED CONSENT
I ,______________________________________, volunteer to take part in the following
research investigation.
I understand that to be eligible for this study I must fit the research volunteer criteria, 
which includes: 1) 21-42 years of age; 2) non-smoker; 3) normal weight' 4) non-athletes; 5) 
have normal and regular menstrual periods and not be post-menopausal; 6) not taking any 
medication, including birth control pills or hormone replacement therapy, unless being treated by 
a physician with GnRHaa therapy (a medication that stops the normal menstrual cycle in 
premenopausal women).
PURPOSE OF THE STUDY
The purpose of this research is to study the consequences of low hormone (estrogen) 
levels on the body's metabolism at rest and during moderate exercise. This will be done by 
comparing women with different hormone (estrogen) levels. For example, the lowest level of 
estrogen is at the time of menses, and highest levels are found about four days before ovulation. 
These levels will be confirmed by blood analysis.
The goal of the study is to increase understanding of how and why many females gain 
weight during menopause (the change of life), a time in which a woman’s body stops producing 
estrogen. This research will focus on the connection between the absence of estrogen, a 
condition which occurs normally at menopause, and the body’s energy balance.
DETAILS OF THE STUDY
I understand I am being asked to participate in a study that will require me to complete a 
one-time 30 minute exercise test on a stationary bicycle at a moderate level of intensity (50% of 
maximal effort). I will be placed in one of four groups of women according to when testing 
occurs during my menstrual cycle. The groups are as follows:
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Group 1: Ten women who currently have normal menstrual periods. They will be tested 
during the time they are having a period.
Group 2: Ten women who currently have normal menstrual periods. They will be tested 
during the early part of their 28 day cycle (between days 8-12).
Group 3: Ten women who are currently receiving a medication from their gynecologist 
that stops their normal menstrual cycle and have been on this medication for at least two 
months and are otherwise healthy.
Group 4: Ten women who have volunteered to be placed on a medication by their 
gynecologist to stop their normal menstrual cycle but have not started this drug therapy yet 
They will be tested before they begin and while on medication.
STUDY PROCEDURES FOR DATA COLLECTION
I understand that I will be asked to perform an exercise test on a stationary bicycle at 
below maximal intensity, and breathe through a tube connected to an instrument that will 
measure the volume of air I breathe and oxygen I use, as well as the carbon dioxide I blow off 
during the test The test will begin at a relatively low exercise intensity and will increase in 
intensity every two minutes for two or three stages. The intensity of this test will be equal to a 
brisk walk. An intravenous (IV) catheter (small tube) will be placed in my arm by a Registered 
Nurse. This will allow blood samples to be drawn prior to the test and at three times during the 
test (@ 10,20, and 30 minutes). I understand I will have a small amount of IV fluid (normal 
saline) passed into the IV catheter during the exercise test so that blood will be easily drawn. 
Approximately 8 ml of whole blood (about 114 teaspoons) will be collected per draw representing 
less than 3 ounces total during the entire exercise test
Before the testing date, I will be asked to comply with the following:
•  Get a good night's sleep before the day of the test
•  Abstain from food and drink (other than water) from midnight until testing time
•  Avoid moderate or vigorous physical activity within 12 hours of testing
•  Empty my bladder prior to testing
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•  Abstain from alcohol consumption within 48 hours of testing
•  Take no over-the-counter drug, i.e.. aspirin, motrin, tylenol, cold & sinus medications, 
etc. within 24 hours of testing
•  Wear loose clothing such as a warm-up suit and rubber soled shoes for walking or 
running for the test procedure.
RISKS AND DISCOMFORTS ASSOCIATED WITH TESTING PROCEDURES 
Exercise: I understand the risks of ‘submaximar exercise testing (exercising below 
maximal effort), according the American College of Sports Medicine 1995 guidelines, are extremely 
small for my age. However, emergency equipment and trained personnel are readily available 
during the exercise test
Having blood drawn through an intravenous (IV) line: I have been told that some risks 
connected with having my blood drawn are
•  temporary discomfort from the needle stick;
•  bruising (and rarely infection) at the needle stick site;
•  possible fainting after blood sampling;
•  possible irritation (redness) along the vein from which blood will be drawn.
I understand that if I tend to faint when I have my blood drawn, I must report it so that safety
measures can be taken to prevent this from happening. I understand I will be lying down when the 
IV  is inserted into my arm, and it will be taped securely. After leaving the testing area, I understand 
I should report any development of redness or infection around the IV site immediately to the 
research office (231-5275) so it can be evaluated promptly.
BENEFITS
I understand that by being in this study I will be contributing to scientific knowledge 
concerning the metabolism (energy burned at rest and during exercise) of postmenopausal females, 
and to help in determining why many of these women gain weight and have difficulty losing weight.
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I, personally, will gain information about my fitness level. I will be given a copy of the results of all 
the fitness testing which will demonstrate my current overall fitness level. This information can be 
used as a basis for an exercise prescription and assist me in developing my fitness goals. The 
‘Personal Fitness Profile* that I will receive will include the results of the preliminary physical fitness 
testing, e.g., muscular strength and flexibility; bloodwork, e.g., blood sugar, blood lipid profile; bone 
thickness scan; body fat percent; lung function test; and a nutritional assessment, based on a three 
day dietary log that I will be asked to keep prior to the stationary bicycle test This profile will given 
to me at no charge.
CONFIDENTIALITY
I have been told that my privacy as a research volunteer will be protected and my identity 
will not be revealed. I have also been told that the information collected during this study will not 
be used in any way that would subject me to public embarrassment or shame. Strict confidentiality 
will be maintained by the study staff. I understand that results of this study may be published, but 
my privacy will be protected and my name and identity will not be published. I understand that my 
research medical record will be kept private and will only be used by staff directly involved with this 
study. It may, however, be inspected by staff from the Louisiana State University Institutional 
Review Board, but will still remain as private information.
COMPENSATION
I understand that LSU and Woman’s Health Research Institute are paying for all testing and 
personnel and I am not responsible for any payments associated with this study. I understand if I 
am being treated with medication (GnRHaa) to stop my normal menstrual cycle that I am 
responsible for purchasing this medication prescribed to me by my physician, since I would be 
taking this medication even if I chose not to participate in this study.
RESEARCH VOLUNTEER RIGHTS
I understand that I may choose not to participate in this study, and I may withdraw from the 
study at anytime with no penalty. This will not have any effect on any treatment, if applicable, at
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the present tame or in the future by my personal physician or staff of the Woman’s Health Research 
Institute or Woman’s Hospital.
I have completely read this consent form. The study has been explained to me and all my 
questions have been answered in person. I understand the purpose of the study and 
the methods that are involved and any possible risks and discomforts. If I have any questions at 
any time during the study, I know I can call the co-investigators, Sheri Melton at (504) 763-9167 or 
Dr. Ellen Brooks at (504) 231-5390, or the principal investigator. Dr. Arnold Nelson at (504) 388- 
2036. I understand that this study has been approved by the Louisiana State University Institutional 
Review Board (IRB) and the Woman’s Hospital Research and Development Council. I understand 
if I have any questions about my rights as a research volunteer or if I wish to report any concerns 
or complaints regarding this study, I can contact the Vice Chancellor of the LS.U. Office of 
Research and Economic Development at (504) 388-5833.
INFORMED CONSENT SIGNATURES 
I have received a signed copy of this consent form.
Research Volunteer Name Printed Volunteer Social Security #  Volunteer
DOB
Research Volunteer Signature Date/Time
Witness
Arnold Nelson, Ph.D. LSU Department of Kinesiology 
Principal Investigator
Sheri Melton, Ph.D. Candidate LSU 
Co-investigator
Ellen Brooks, R.N., Ph.D. Woman’s Health Research Institute, Co-investigator
Hoyt Ayres, M.D. Woman's Health Research Institute, Study Medical Monitor
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VITA
Sheri Anne Melton was bom in Dallas, Texas, on January 12,1947. She 
attended both public and parochial schools in Dallas, and graduated from Bishop 
Dunne Catholic High School in 1965. For two years she worked as an accounting 
clerk at several Dallas-based companies. She moved to New Orleans in 1967 
where she attended Loyola University. She graduated from that institution in 1971 
with a bachelor of arts degree in Economics.
For the next fourteen years, she held several positions in banking, urban 
planning, marketing and hospital unit administration. In 1985, she made the 
decision to enter graduate school in Health and Physical Education at the 
University of New Orleans, where she graduated in 1987. Her professional career 
after graduation encompassed personal trainer, fitness consultant, manager of a 
fitness center, orthopedic rehab and cardiac rehab. During these years, her 
athletic interests and abilities grew. She competed in biathlons, triathalons, 
running, cycling and won several awards in her age division. In 1990, she 
competed in the United States Cycling Federation National Championships, 
Masters Time Trial (40km). In 1992, she earned a first degree black belt in Tae 
Kwon Do.
In 1993, she was accepted into the doctoral program in the Kinesiology 
Department at Louisiana State University, where she worked as a graduate 
assistant teaching tennis, exercise physiology labs and several undergraduate 
lecture classes, including community health and exercise testing and prescription. 
During her years at L.S.U., she was involved in several animal research projects.
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Her major research interest is women’s health, especially postmenopausal issues 
relating to estrogen status and its relationship to metabolism. She has pursued 
her doctor of philosophy degree in Kinesiology with a major emphasis in Exercise 
Physiology and a minor in Nutrition. Upon graduation in December of 1997, she 
plans to pursue a teaching/research/writing career.
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